Mineral cation complex compositions, formulations therof, and methods of use therof

ABSTRACT

The disclosure provides compositions and formulations for the treatment and mitigation disease as well as the restoration of cells to a state of metabolic homeostasis. The disclosure further provides exemplary methods of administering a therapeutically effective amount of a composition or formulation comprising a mineral cation complex and ionic salt to a subject for the treatment of disease or disorder. The disclosure further provides exemplary methods of administering a therapeutically effective amount of a composition or formulation comprising a mineral cation complex and ionic salt to a subject for the maintenance or restoration of cellular metabolic homeostasis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. application Ser. No. 17/466,974,filed Sep. 3, 2021, now allowed, which claims benefit of, and priorityto, U.S. application Ser. No. 63/074,982 filed on Sep. 4, 2020, thecontents of each of which are hereby incorporated by reference in theirentireties.

FIELD OF THE INVENTION

The disclosure generally relates to compositions and formulations foruse in treating and mitigating disease as well as restoring ormaintaining metabolic homeostasis of healthy cells.

BACKGROUND

The following description includes information that may be useful inunderstanding the present invention. It is not an admission that any ofthe information provided herein is prior art or relevant to thepresently claimed inventions, or that any publication specifically orimplicitly referenced is prior art.

The prevalence of disease remains a problem in society today.Alternatively, or in addition, a loss of cellular metabolic homeostasisremains a problem in society today. Organisms constantly face exposureto, and fall victim to, numerous pathogenic agents which can result inphysiological consequence, physical impairment, or even death. There isa long-felt yet unmet need in the art for safe and effectivecompositions and formulations that can treat disease as well as maintainhealth. The disclosure provides solutions for these unmet needs.

SUMMARY

The following embodiments and aspects thereof are described inconjunction with systems, tools and methods which are meant to beexemplary, not limiting in scope.

In various embodiments, one or more of the above-described problems havebeen reduced or eliminated, while other embodiments are directed toother improvements.

The disclosure provides a composition comprising: a hexa-aqua moietycomprising six water molecules, one or more cationic mineral(s), and oneor more ionic salt(s); wherein the one or more cationic mineral(s) formsix coordinate bonds with water ligands to form a hexa-aqua complex.

In some embodiments of the compositions of the disclosure, the one ormore cationic minerals comprise chromium, cobalt, copper, gold, iron,manganese, magnesium, molybdenum, nickel, platinum, silver, vanadium,and zinc.

In some embodiments of the compositions of the disclosure, the one ormore ionic salts comprise nitrogen, phosphorous, potassium, sulfur, andhydrogen.

In some embodiments of the compositions of the disclosure, thecomposition further comprises a pharmaceutically acceptable carrier.

In some embodiments of the compositions of the disclosure, thecomposition further comprises one or more botanical agent(s). In someembodiments, the one or more biological agent(s) comprises Graviola(Annona muricate), Bitter Melon (Momordica charantia), Esplanheira Santa(Maytenus illcifolia), Mullaca (Physolis angulate), Vasourinho (Scopariadulcis), Mutamba (Guazuma ulmifola), Suma (Pfaffia paniculata), Cat'sClaw (Uncaria tomantosa) and Blood Root (Sanguinaria canadensis). Insome embodiments, the one or more biological agent(s) comprises Annonamuricate, Momordica charantia, Maytenus illcifolia, Physolis angulate,Scoparia dulcis, Guazuma ulmifola, Pfaffia paniculata, Uncaria tomantosaand Sanguinaria canadensis.

The disclosure provides a formulation comprising a composition of thedisclosure, wherein the formulation is suitable for administration in adroplet form, an aerosol form, a vaporized form or a nebulized form.

The disclosure provides a formulation comprising a composition of thedisclosure, wherein the formulation is suitable for administration in aliquid form, a suspension form or a rehydrated form.

The disclosure provides a formulation comprising a composition of thedisclosure, wherein the formulation is suitable for administration in asemi-solid form.

The disclosure provides a formulation comprising a composition of thedisclosure, wherein the formulation is suitable for administration in asolid form, a pill form, a tablet form or a capsule form.

In some embodiments of the formulations of the disclosure, theformulation comprises one or more of an excipient, a filler, a viscosityadjusting agent, a tonicity adjusting agent, a pH adjusting agent, abuffering agent, a purging agent, a co-solvent agent, a preservativeagent, a suspension agent, a surfactant agent, a filler agent, a bulkingagent, a solvent agent, and a humectant agent. In some embodiments, thetonicity adjusting agent comprises sodium chloride or dextrose. In someembodiments, the pH adjusting agent comprises sodium hydroxide,hydrochloric acid or sulphuric acid. In some embodiments, the bufferingagent comprises sodium citrate, sodium phosphate or citric acid. In someembodiments, the purging agent comprises nitrogen. In some embodiments,the co-solvent agent comprises alcohol, polyethylene glycol (PEG) 400 orpropylene glycol. In some embodiments, the preservative agent comprisesbenzalkonium chloride, ethanol, propylene glycol, beczoyl alcohol,chlorobutanol or methyl paraben. In some embodiments, the suspensionagent comprises carboxymethylcellulose (CMC) or sodium CMC. In someembodiments, the surfactant agent comprises poractant, poracant alfa,polysorbate 80 or polysorbate 20. In some embodiments, the humectantagent comprises glycerin.

In some embodiments of the formulations of the disclosure, a dropletform comprises a droplet size of between 0.5 μm and 7.0 μm, inclusive ofthe endpoints.

In some embodiments of the formulations of the disclosure, compositionis suitable for administration by a nebulizer. In some embodiments, thenebulizer comprises a nozzle array and an aqueous chamber. In someembodiments, the nozzle array comprises an air jet nebulizer, anelectronic nebulizer, an ultrasonic nebulizer, a vibrating meshnebulizer, a vibrating membrane nebulizer, a vibrating plate nebulizer,or a vibration generator.

The disclosure provides a device comprising a composition of thedisclosure.

The disclosure provides a device comprising a formulation of thedisclosure.

In some embodiments of the devices of the disclosure, including thosedevices comprising a composition or a formulation of the disclosure, thedevice comprises a nebulizer, a humidifier, a vaporizer, or an inhaler.

The disclosure provides a method of maintaining or restoring metabolicfunction in a cell, comprising contacting the cell and a composition ofthe disclosure under conditions suitable for the composition to traversea membrane of the cell, thereby maintaining or restoring metabolicfunction in the cell. In some embodiments, the cell is contacted invitro, ex vivo, or in vivo.

The disclosure provides a method of maintaining or restoring metabolicfunction in a cell, comprising contacting the cell and a formulation ofthe disclosure under conditions suitable for the formulation to traversea membrane of the cell, thereby maintaining or restoring metabolicfunction in the cell. In some embodiments, the cell is contacted invitro, ex vivo, or in vivo.

The disclosure provides a method of reducing or preventing infection ofa cell, comprising contacting the cell and a composition of thedisclosure under conditions suitable for the composition to traverse amembrane of the cell, thereby reducing or preventing infection of thecell. In some embodiments, the cell is contacted in vitro, ex vivo, orin vivo.

The disclosure provides a method of reducing or preventing infection ofa cell, comprising contacting the cell and a formulation of thedisclosure under conditions suitable for the formulation to traverse amembrane of the cell, thereby reducing or preventing infection of thecell. In some embodiments, the cell is contacted in vitro, ex vivo, orin vivo.

The disclosure provides a method for treating a disease or disorder,comprising administering to a subject a therapeutically effective amountof a composition of the disclosure.

The disclosure provides a method for treating a disease or disorder,comprising administering to a subject a therapeutically effective amountof a formulation of the disclosure.

In some embodiments of the methods of the disclosure, treating comprisesreducing a severity of at least one sign or symptom of the disease ordisorder. In some embodiments, the disease or disorder is a loss ofhomeostasis of cellular metabolism. In some embodiments, the disease ordisorder comprises at least one cell, cell type, tissue, or organpresenting an anaerobic cellular state. In some embodiments, the diseaseor disorder comprises an infectious disease, a proliferative disorder,an inflammatory disorder, a neurological disorder, a metabolic disorder,a cardiovascular disorder, a respiratory disorder, a blood-relateddisorder, a genetic disorder, an epigenetic disorder, a musculardisorder, a endocrine disorder, a hormonal disorder, a digestivedisorder or a disorder secondary to a medical procedure or injury. Insome embodiments, the disorder comprises Lyme Disease. In someembodiments, the disorder further comprises a disorder secondary orco-morbid with Lyme Disease. In some embodiments, the disorder is aninfection. In some embodiments, the infection is a viral infection. Insome embodiments, the infection is mediated by a coronavirus. In someembodiments, the infection is mediated by SARS-COV2. In someembodiments, the disorder comprises Hepatitis C. In some embodiments,the disorder comprises African Swine Fever. In some embodiments, thedisorder comprises a tumor or a cancer. In some embodiments, thedisorder comprises a wound from a medical procedure or an injury.

The disclosure provides a method for maintaining or restoring cellularmetabolic homeostasis, comprising administering to a subject atherapeutically effective amount of a composition of the disclosure.

The disclosure provides a method for maintaining or restoring cellularmetabolic homeostasis, comprising administering to a subject atherapeutically effective amount of a formulation of the disclosure.

In some embodiments of the methods of the disclosure, the composition isadministered systemically. In some embodiments, the composition isadministered orally, intranasally, intravenously, intraperitoneally,subcutaneously or intramuscularly.

In some embodiments of the methods of the disclosure, the composition isadministered locally. In some embodiments, the composition isadministered topically, intraocularly, intraspinally,intracerebroventricularly, intraosseously or intratumorally.

In some embodiments of the methods of the disclosure, the formulation isadministered systemically. In some embodiments, the formulation isadministered orally, intranasally, intravenously, intraperitoneally,subcutaneously or intramuscularly.

In some embodiments of the methods of the disclosure, the formulation isadministered locally. In some embodiments, the formulation isadministered topically, intraocularly, intraspinally,intracerebroventricularly, intraosseously or intratumorally.

The disclosure provides a method of conditioning an environment,comprising contacting a composition of the disclosure or a formulationof the disclosure and an element of the environment, wherein theconditioning reduces a measured value of a feature of a pathogen on theelement when compared to a threshold value of the feature. In someembodiments, the element comprises one or more of a manmade material, anaturally-occurring material, a surface, a sub-surface, an interface, anarea, a volume, an interior and an exterior. In some embodiments, theelement comprises one or more of a portable object, a medical object, anedible object, a food object, a plant and an animal. In someembodiments, the element interacts with one or more of soil, air,atmosphere, and water. In some embodiments, the element comprises one ormore of soil, air, atmosphere, and water. In some embodiments, theenvironment comprises a terrestrial environment or an aquaticenvironment. In some embodiments, the aquatic environment comprises oneor more of an ocean, a river, a stream, a lake and a reservoir. In someembodiments, the feature of a pathogen comprises one or more of anabundance, a function, an activity, a virulence, a level of infectivity,and a rate of infectivity. In some embodiments, the pathogen comprisesone or more of a virus, a bacteria, a fungus, a protozoa, an amoeba, amicrobe, a worm and an insect.

The disclosure provides a composition and formulation for treating andmitigating diseases while bolstering metabolism of healthy cellsincludes at least one mineral cation bound by a hexa-aqua ligand complexand at least one ionic salt in a pharmaceutically acceptable carrier.The mineral cation hexa-aqua complex and ionic salt composition mayfurther be combined with other pharmaceutically acceptable carriers fordelivery with other ingredients.

In some embodiments, the composition and formulation as manufacturedprovides a delivery system for moving the mineral cation hexa-aquacomplex and ionic salt to the target area of a cell. The ligand complexenables the functional properties of the cationic minerals withoutcompromising the effectiveness and structure of the complex. Thus, it isable to travel throughout the body until it reaches the target cellswhere the ionic contents are then released into the cells. Thecomposition allows for appropriate delivery of agents that are able todisrupt metabolic function of diseased and/or dysfunctional cells, whilesimultaneously impacting the metabolic homeostasis of healthy cells in apositive manner. It must be stressed that all minerals discussed can beintroduced to the target cells using the hexa-aqua complex deliverysystem without the aid of additional compositions. The bioavailablemineral cation hexa-aqua complex and ionic salt composition is highlyeffective, but the use of botanicals, vitamins and mineral supplements,and formulation additives improve the performance of the mineral cationhexa-aqua complex and ionic salt composition alone.

The composition and delivery mechanism may be used to treat a myriad oforganismal conditions including infection or infectious disease,proliferative disorder, inflammatory disorder, neurological disorder,traumatic tissue injury, and any ailment or dysfunction resulting fromanaerobic or atypical cellular metabolism. Additionally, the compositionand delivery system may be used in nutrition related problems, and bringcells to a state of metabolic homeostasis. Thus, the composition may beused for the general well-being of persons on a daily basis taking intoaccount factors such as, sex, stress factors, genetics, and theenvironment. Moreover, the composition may be used to mitigate orprevent accumulation of pathogens in the terrestrial environment, onobjects, or within food products.

The composition may take a plurality of different forms each having adifferent bioavailable cationic mineral or minerals, and ionic salt orsalts in the same or different proportions. Different mechanisms foradministering the mineral cation hexa-aqua complex and ionic saltcomposition may be used to ensure the bioavailable ionic contents reachthe target area. For example, the mineral cation hexa-aqua complex andionic salt composition may be introduced into the body of a subject(organism) by at least one of ingestion, inhalation, injection,capsules, suppository, transdermal patches, and cream or suave for useas a topical application. In certain embodiments, the subject may be ahuman. In another embodiment, subject may me a mammal. In anotherembodiment, the subject may be a plant.

The disclosure provides a composition for mitigating pathogens, treatingdiseases, and bolstering or maintaining cellular metabolic homeostasisincludes a therapeutically effective amount of a mineral cationhexa-aqua complex and ionic salt in a pharmaceutically acceptablecarrier. The cationic mineral, or minerals, of the mineral cationhexa-aqua complex and ionic salt composition are bound in a hexa-aquacomplex enabling transport of said ionic contents through a biologicalsystem to a target cell. The mineral cation of the mineral cationhexa-aqua complex and ionic salt composition may be at least one of, orany combination of, actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, magnesium, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,roentgenium, ruthenium, rutherfordium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formmetal aquo complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may be atleast one of, or any combination of, actinium, cadmium, chromium,cobalt, copper, gold, hafnium, iridium, iron, lanthanum, manganese,mercury, molybdenum, nickel, niobium, osmium, palladium, platinum,rhenium, rhodium, ruthenium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumthat are able to form hexa-aqua complexes. In another embodiment, themineral cation of the mineral cation hexa-aqua complex and ionic saltcomposition may be at least one of, or any combination of, chromium,cobalt, copper, gold, iron, manganese, magnesium, molybdenum, nickel,platinum, silver, vanadium, or zinc and all other forms of theseminerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cations of the mineral cation hexa-aqua complexand ionic salt composition may be copper, magnesium, and zinc. Incertain embodiments, the ionic salt of the mineral cation hexa-aquacomplex and ionic salt composition may be at least one of bicarbonate,calcium, chloride, sodium, sulfur, nitrogen, phosphorous, and potassium.In other embodiments, the ionic salts of the mineral cation hexa-aquacomplex and ionic salt composition may be ammonium and hydrogen sulfate.In certain embodiments, the pharmaceutically acceptable carrier of themineral cation hexa-aqua complex and ionic salt composition may be atleast one of sugars, starches, cellulose or cellulose-derivatives,powdered tragacanth, malt, gelatin, talc, excipients, oils, glycols,polyols, esters, agar, alginic acid, pyrogen-free water, isotonicsaline, Ringer's solution, ethyl alcohol, phosphate buffer solutions,cream, emulsion gel, liposome, nanoparticle, ointment, and othernon-toxic comparative substances employed in pharmaceuticalformulations. In other embodiments, the pharmaceutically acceptablecarrier of the mineral cation hexa-aqua complex and ionic saltcomposition may be water.

Mineral cation ligands can be classified as metal coordination complexesand can be a versatile platform for design of novel compositions withquite different properties from those of purely organic compounds. Themetals are selected for their variable oxidation states, coordinationnumbers and ability to bind to a wide variety of salts including sulfur,nitrogen, phosphorus and potassium. Such complexes can be utilized inmany formulations directed at other higher organism health. The cationicminerals are associated with amines at inception during themanufacturing process and transition into hexa-aqua ligands leaving thenitrogen and hydrogen.

The disclosure provides a method for producing a mineral cationhexa-aqua complex and ionic salt composition for treating and mitigatingdisease while also bolstering metabolic homeostasis of healthy cells,comprising forming hexa-coordinated complexes with one or more cationicminerals by dissolving one or more ionic salts in water, wherein thecomposition comprises at least one cationic mineral complex encapsulatedby hexa-aqua ligands. In some embodiments, amines attached to metal ionswhich are slowly absorbed as the ligand structure moves toward waterligands establishing a hexa-aqua complex and freeing up the amines forassimilation along with other antioxidants including hydrogen, andsulfur and nitrogen salts. In certain embodiments, other formulationsmay include other salts that comprise phosphorous, nitrogen, potassium,sodium, chloride, calcium, and/or bicarbonate in combination with othermetals. A prepared mixture includes at least one organic mineral complexencapsulated by hexa-aqua ligands. In some embodiments, the one or morecationic minerals comprise chromium, cobalt, copper, gold, iron,manganese, magnesium, molybdenum, nickel, platinum, silver, vanadium,and zinc. In some embodiments, the one or more ionic salts comprisenitrogen, phosphorous, potassium, sulfur, and hydrogen. In certainembodiments, a diluted mixture may be combined with a pharmaceuticallyacceptable carrier for delivery with other ingredients.

In some embodiments, preparing the composition includes generating asolution of ammonium hydrogen sulfate using sulfuric acid (without pHbuffering), diluting the ammonia hydrogen sulfate with water to form amixture; adding specific minerals from the designated selection to themixture in a salt form; and agitating the mixture comprising theammonium hydrogen sulfate, sulfuric acid, water, and the mineral saltingredients. In certain embodiments, other salts may be incorporated inthe beginning formulation, or other formulations, with other mineralsutilizing the basic concept as described above with substitution of thesalt preparation.

In some embodiments, generating a solution of ammonium hydrogen sulfatecomprises in the following order, a) mixing ammonium sulfate withdistilled water; and b) mixing sulfuric acid with the mixture comprisingammonium sulfate and distilled water, wherein the components of saidmixture are added at a rate that does not result in an exothermicreaction in excess of 300° C. during either a) or b). In someembodiments, the concentration of ammonium sulfate used in generatingthe solution of ammonium hydrogen sulfate is about 20% w/v or less. Insome embodiments, the ammonium sulfate used in generating the solutionof ammonium hydrogen sulfate is mixed with distilled water at a ratio of3:2 or less, ammonium sulfate to distilled water. In some embodiments,the ammonium sulfate used in generating the solution of ammoniumhydrogen sulfate is mixed with distilled water at a ratio of 1:1 orless, ammonium sulfate to distilled water. In some embodiments, theconcentration of sulfuric acid used in generating the solution ofammonium hydrogen sulfate is about 18 M. In some embodiments, thesulfuric acid used in generating the solution of ammonium hydrogensulfate is mixed with the mixture comprising ammonium sulfate anddistilled water at a ratio of 1:1 or more, sulfuric acid to mixturecomprising ammonium sulfate and distilled water. In some embodiments,the sulfuric acid used in generating the solution of ammonium hydrogensulfate is mixed with the mixture comprising ammonium sulfate anddistilled water at a ratio of 2:1 or less, sulfuric acid to mixturecomprising ammonium sulfate and distilled water. In some embodiments,the mixture comprising ammonium sulfate, distilled water, and sulfuricacid is cooled to a temperature of less than 65.5° C. prior to addingone or more cationic minerals. In some embodiments, the one or morecationic minerals are added so that the ratio of minerals is optimizedfor bioavailability and avoidance of adverse mineral interactions of abiological system. In some embodiments, the one or more cationicminerals are added to the mixture of ammonium sulfate, distilled water,and sulfuric acid at ratio of at least 1:1:1, wherein the one or morecationic minerals are zinc, copper, and magnesium. In some embodiments,the one or more cationic minerals are added to the mixture of ammoniumsulfate, distilled water, and sulfuric acid at a ratio of no more than3:1:1, wherein the one or more cationic minerals are zinc, copper, andmagnesium. In some embodiments, the method further comprises combiningthe composition comprising ammonium hydrogen sulfate, sulfuric acid,water, and one or more cationic minerals with a pharmaceuticallyacceptable carrier. In some embodiments, the method further comprisescombining the composition comprising ammonium hydrogen sulfate, sulfuricacid, water, and one or more cationic minerals one or more botanicalagent(s). In some embodiments, the one or more biological agent(s)comprises Graviola (Annona muricate), Bitter Melon (Momordicacharantia), Esplanheira Santa (Maytenus illcifolia), Mullaca (Physolisangulate), Vasourinho (Scoparia dulcis), Mutamba (Guazuma ulmifola),Suma (Pfaffia paniculata), Cat's Claw (Uncaria tomantosa) and Blood Root(Sanguinaria canadensis).

In some embodiments of the present disclosure the combination of anacidic base with one or more selected minerals optimizes theavailability of the mineral(s) in appropriate purity levels for thetargeted disease, condition, indication or symptom. Thus, in someembodiments of the present disclosure, the resulting combined mixtureoptimizes the availability of the mineral(s) (both individually and in acombined mixture) for the treatment of a disease, condition, indicationor symptom.

DETAILED DESCRIPTION

Organisms (humans, animals, and plants) are frequently subject tomalnutrition and disease. Moreover, organisms experiencing states ofmalnutrition are at greater risk of contracting, developing, orperpetuating a disease or disorder. Macronutrients, micronutrients, andtrace minerals help facilitate homeostasis of cellular metabolicfunctionality.

Acquisition of these nutrients is primarily accomplished through dietaryintake, however access to food and nutrients, and appropriate balance ofnutrients, is often limited and unmet. A variety of methods are used tosupplement diet, but at unsatisfactory levels. Over-the-counter vitaminsand minerals may be used, however, the levels of nutrientbioavailability in these supplements are inadequate.

Current methods of nutrient supplementation often utilize compounds thatare minerals bound as oxides and salts. Both the minerals and salts areprocessed in the digestive system of a subject and must be split intoionic states through the processes of digestion. Moreover, thephysiological process involving splitting the mineral from the saltresults in an inefficient energy cost and subsequently a more limiteddegree of acquisition and use of nutrients. Thus, alternative methods ofnutrient delivery are important to better manage malnutrition anddisease.

Cells under diseased or dysfunctional states utilize bioavailablenutrients differently from that of healthy cells. Therefore, it is alsodesirable to generate nutrient-based compounds for use against a widevariety of diseases using a delivery system ensuring that associatedcompounds reach the intended target cells.

The invention is related to a mineral cation hexa-aqua complex and ionicsalt composition for treating and mitigating diseases as well asbolstering or maintaining metabolic function of healthy cells. Moreparticularly, the present disclosure relates to a composition havingbioactive elements that are able to interrupt the metabolic pathway ofcells presenting with disease or disease-provoked atypical metabolismwhile also positively impacting the metabolic pathway of healthy cells.

Minerals and Cellular Metabolism

Cationic mineral ligands and ionic salts are the result of amanufacturing process resulting in mineral ligands bound by six watermolecules. The ligands act independently of one another in formulation.This allows the ionic salts and cationic minerals the ability combinewith other molecules immediately. This capability provides a new tool toscience for metal therapeutic compositions that can be used in newformulations.

Transition metals may be used in the mineral cation hexa-aqua complexand ionic salt composition. In certain embodiments, transition metalsfor use in the mineral cation hexa-aqua complex and ionic saltcomposition may include, but are not limited to, elements such aschromium, cobalt, copper, gold, iron, manganese, magnesium, molybdenum,nickel, platinum, silver, vanadium, and zinc. Minerals such as these mayfunction in various biological processes, for example, cell metabolismand performing the cell cycle.

Nutrients that are essential to biological function include, but are notlimited to, sodium, chloride, potassium, calcium, phosphorus, magnesium,sulfur, iron, zinc, iodine, selenium, copper, manganese, fluoride,chromium, molybdenum, nickel, silicon, vanadium, and cobalt. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise one or more of sodium, chloride, potassium,calcium, phosphorus, magnesium, sulfur, iron, zinc, iodine, selenium,copper, manganese, fluoride, chromium, molybdenum, nickel, silicon,vanadium, and cobalt. Other biologically important elements includecarbon, nitrogen, hydrogen and oxygen that can be absorbed from the airwhile other nutrients must be acquired (traditionally through absorptionin the stomach) including water and other minerals. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise one or more of carbon, nitrogen, hydrogen, andoxygen. In certain embodiments, the mineral cation hexa-aqua complex andionic salt composition may comprise one or more of sodium, chloride,potassium, calcium, phosphorus, magnesium, sulfur, iron, zinc, iodine,selenium, copper, manganese, fluoride, chromium, molybdenum, nickel,silicon, vanadium, cobalt, carbon, nitrogen, hydrogen, and oxygen.

Nutrients (elements) play key roles in numerous biological functions.The following are provided as general non-limiting examples of hownutrients influence biological mechanisms.

Calcium plays a role in things such as bone and tooth development,enzyme activity, blood pressure regulation, muscle contraction, neuronalsignaling, and blood clotting. Carbon plays a role in such things asacting as the primary component of macromolecules in biological systems.Chloride plays a role in things such as fluid regulation, bloodpressure, and pH regulation. Chromium plays a role in things such asblood sugar regulation, and carbon metabolism. Cobalt plays a role inthings such as cell division, amino acid synthesis, and co-enzymefunctionality. Copper plays a role in things such as general metabolism,red blood cell formation, neurotransmitter regulation, and reduction offree radicals. Fluoride plays a role in things such as bone and toothstructural maintenance. Iron plays a role in things such as red bloodcell functionality, amino acid synthesis, collagen synthesis,neurotransmitter synthesis, and hormone synthesis. Hydrogen plays a rolein things such as formation and structure of macromolecules, andmetabolic functionality. Iodine plays a role in things such as hormonesynthesis and general metabolism. Nitrogen plays a role in things suchas amino acid synthesis. Magnesium plays a role in things such as boneand tooth development, blood pressure regulation, muscle contraction,neuronal impulses, blood clotting, and enzyme functionality. Manganeseplays a role in things such as amino acid metabolism, cholesterolmetabolism, and carbohydrate metabolism. Molybdenum plays a role inthings such as enzyme functionality, and removal of toxins. Nickel playsa role in such things as enzyme functionality and red blood cellmaintenance. Oxygen plays a role in things such as signaling,metabolism, and cellular respiration. Phosphorus plays a role in suchthings as bone and tooth development, carbohydrate and lipid metabolism,and growth/maintenance and development. Potassium plays a role in thingssuch as regulating fluids, maintain myocardial contractions, and generalmuscle contraction. Silicon plays a role in such things as collagen andelastin synthesis for development and maintenance of connective tissue.Selenium plays a role in things such as hormone regulation, nucleic acidsynthesis, and cellular defense. Sodium plays a role in things such asregulating fluids, neuronal impulses, and muscle contraction. Sulfurplays a role in things such as protein synthesis, and antioxidantproduction. Vanadium plays a role in such things as immune response andgrowth factors. Zinc plays a role in things such as amino acid andnucleic acid biosynthesis, immune system functionality, and cellulardivision.

It is important to recognize that these nutrients (elements) interactwith each other in biological systems. Elements in a biological systemcan impact or influence other (one or more) elements in a biologicalsystem in a dynamic fashion. Too much of one element (e.g., mineral) mayeasily disrupt equilibriums of other elements (e.g., other minerals)necessary to perform biological function. The phenomenon of mineralinteractions has been well documented. Generally available mineralinteraction charts provide indications of the interaction relationshipsbetween and among the minerals being combined in order to determineappropriate optimized mixtures of the minerals in the compositions ofthe present disclosure. For example, as shown by (O'Dell, B., MineralInteractions Relevant to Nutrient Requirements, J Nutrition, 1989.119:12 pp. 1832-1838) the mineral nutrient pairs comprisingsodium-potassium, calcium-magnesium, manganese-iron, iron-copper, andzinc-copper all present with potential negative interactions with oneand other when out of balance, as these particular interactions havebeen shown to influence the uptake and/or status of one and other. Usingsuch information and the present disclosure, one skilled in the art canidentify the selection of minerals and the exact mineral ratios for usein the compositions and/or formulations of the instant disclosure tooptimize treatment of any specific disease, condition, indication orsymptom without negatively disrupting intrinsic elements present in abiological system. The combining of a base, such as an acidic base, withthe minerals can be repeated for multiple mineral additions based on themineral interaction charts requirements and the specific disease,condition, indication or symptom. For such information, see also, e.g.,Interactive Nutrition Facts Label, Vitamins and Minerals Chart 1, U.S.Food & Drug Administration, March 2020; B. L. O'Dell, MineralInteractions Relevant to Nutrient Requirements, J Nutr. 119(12Suppl):1832-1838, Dec. 1999; Advanced Nutrition and Human Metabolism6^(th) Ed., S. S. Gropper and J. L. Smith, Cengage Learning, Jun. 1,2012, 608 pages; and, Advanced Nutrition: Macronutrients,Micronutrients, and Metabolism 3^(rd) Ed., C. D. Berdanier and L. A.Berdanier, CRC Press, Jul. 7, 2021, 592 pages. Therefore, it isimperative that nutrients in a biological system remain balanced toallow for optimal functionality.

Thus, when introducing ectopic minerals to a biological system carefulconsideration must be taken to generate positive outcomes whilemitigating any negative effects that may occur as a result ofinappropriately balanced nutrients. The phenomenon of mineralinteractions is believed to spawn from instances where elements that mayshare common chemical parameters may compete for common metabolic sites.Mineral interactions and mineral balance may be exclusive to anindependent biological system, each requiring specific parameters ofparticular minerals. The mineral cation hexa-aqua complex and ionic saltcomposition of the instant invention is tailored to maximize efficacy ofmineral ion delivery, wherein the mineral contents are balanced in sucha way as to mitigate any potential consequence of unfavorable mineralinteractions (e.g., that may lead to deleterious biological responses),while still being effective in treating organisms infected with apathogen or experiencing a disease pathology (e.g., cancer), andsimultaneously bolstering or maintaining metabolism of healthy cells.

As previously stated, nutrients (elements) play a significant role innumerous biological functions, one of which being cellular respiration.Cellular respiration is the metabolic pathway by which cells procureenergy. Cellular respiration in higher organisms may involve severalmetabolic pathways: (1) glycolysis, (2) pyruvate oxidation, (3) citricacid cycle, and (4) oxidative phosphorylation. Glycolysis occurs in thecytosol of cells and functions by breaking down glucose and generatingpyruvate, ATP, and NADH. Pyruvate oxidation occurs in the mitochondrialmatrix where pyruvate from glycolysis is converted into Coenzyme A(acetyl CoA), CO₂ is released, and NADH is generated. The citric acidcycle occurs in the mitochondrial matrix where acetyl CoA from pyruvateoxidation undergoes a series of cyclical reactions releasing CO₂, andgenerating ATP, NADH, and FADH₂. The charged energy carriers (NADH andFADH₂) are then used in oxidative phosphorylation in mitochondria wherecarrier molecules transfer electrons through an electron transport chainallowing for protons present in the matrix to build up in theintermembrane space forming a concentration gradient sufficient togenerate ATP by flowing back to the matrix through an enzyme called ATPsynthase, wherein oxygen accepts electrons and takes up protons to formwater.

While only oxidative phosphorylation directly requires oxygen, bothpyruvate oxidation and the citric acid cycle require oxidativephosphorylation to operate. Glycolysis is the only cellular respirationmetabolic pathway, of the four previously listed cellular respirationmetabolic pathways, that can occur without oxygen. When glycolysis takesplace without oxygen it undergoes a slightly different process referredto as fermentation. For example, lactic acid fermentation is a processsimilar to glycolysis (as glucose is broken down), however the resultingpyruvate is further converted to lactate by oxidizing NADH to NAD⁺,where NAD⁺ may be recycled and once more used for either glycolysis orlactic acid fermentation. The process of fermentation is relativelyquick, however produces less net ATP than if oxidative phosphorylationwere to run to completion.

The Kreb's cycle (citric acid cycle) is a metabolic pathway of higherorder organisms where the parallel use of available fuels, oxygen,water, and other essentials to life in an aerobic world follow the samebasic metabolism of the sugars, fats and proteins to form a structure.The basic oxygen driven metabolism drives the continuation of bothanimals and higher plants. The metabolic system is a well-documented andfamiliar process involving the basic steps to produce a “higher” form oflife. The protection provided by at least thirty-two steps in theprocess provides a system that protects the oxygen driven animals andplants. The basic knowledge we are incorporating in the instantinvention can defeat lower order organisms, including diseases becausethe diseases follow a different metabolic pathway.

Lower order organisms are not nearly as complex regarding the metabolicpathway as the higher organisms (e.g., human or tree). Some prokaryotesperform aerobic or anaerobic metabolism, or switch between the two. Someprokaryotes utilize special enzymes and pathways that allow them tometabolize nitrogen or sulfur containing compounds, wherein in someinstances nitrogen or sulfur containing compounds may be used as thefinal electron acceptor in the electron transport chain. The cyclefollowed by the lower order pathogens such as bacteria and fungi followa less complicated process that allows the disease to multiply at analmost exponential rate based on available resources in an anaerobiccycle that has far fewer steps. The pathogens utilizes all availableminerals, sugars, fats and proteins to fuel the reproduction of cellsusing the abbreviated anaerobic cycle; subsequently the higher the rateof replication, the less oxygen available for healthy tissuessurrounding the disease. Reduced oxygen aids in the fermentation processthat is part of the favorable conditions required for the exponentialgrowth of all organisms using the anaerobic cycle, including cancer.

Furthermore, cells infected by various pathogens, or experiencingdiseased pathology (e.g., cancer), have been shown to influence or altera ‘host’ cell's basal metabolism. An example of this altered metabolismis exhibited by said pathogen-afflicted or diseased-afflicted cells bythe visualization of increased glucose uptake and fermentation ofglucose. It is believed that this occurs to promote growth, survival,proliferation, and long-term maintenance of the afflicted or diseasedcell(s). This particular metabolic alteration is known as the WarburgEffect.

Pathogens affecting higher organisms have an advantage because of theirability for exponential growth due to the use of their shorter metabolicpathway versus the Krebs cycle. Similarly, cells infected with apathogen or cells with a disease pathology (e.g., cancer) often alterthe metabolism of the cell to be more amenable for the persistence ofthe pathogen or disease. The mineral cation hexa-aqua complex and ionicsalt composition exploits the flaw in the exponential expansion of thepathogen and/or altered metabolism of the afflicted cell. Specifically,the flaw in pathogen or the afflicted cell is exploited by using themineral gathering mechanism of the pathogen or afflicted cell againstitself. Lower order organisms (e.g., pathogens) gather the necessaryminerals and other building blocks in an amount proportional to theiravailability in the environment. Moreover, cells experiencing alteredmetabolism by means of pathogen infection or disease pathology, oftenexhibit dysregulation of ion channels which may allow for theinappropriate accumulation of ionic material. Both the metabolismexhibited by pathogens and the altered metabolism from infected ordiseased cells differs from the metabolic processes exhibited by healthycells from higher organisms which only accumulate, or appropriatelyregulate/maintain, enough of the elements and building blocks to satisfythe requirements of cellular respiration, particularly the Kreb's cycle.

Thus, the cells of higher organisms will only incorporate compositionsof the disclosure at a rate necessary for survival and lower organisms(including pathogens), as well as infected and diseased cells willaccumulate minerals in an amount that is toxic. Therefore, providing ahigh concentration of ionic minerals to an infection or diseased area ofa subject (higher organism) would result in a toxic level of the mineralcations to a pathogen, an infected cell, or a diseased cell and allowsurvival of healthy cells so long as the dosage rate of the mineralcations is below the toxic level for the subject. There is a toxic levelfor even higher order organisms, but the amount of the minerals can becalculated to destroy pathogens, infected cells, or diseased cells withlittle to no effect on the healthy cells of higher organism. Killing thedisease, infection, or pathogen agent can occur at proper dosages of themineral cations while the healthy cells of the subject would only gatherthe amount of mineral cations necessary to complete the Krebs Cycle andreject the excess minerals.

The use of highly bio-available mineral cation hexa-aqua complex andionic salt composition at a rate that will kill pathogens, infectedcells, and diseased cells without impairing the function of the higherorganism provides the active complex of the composition. The ligandsystem transports all the minerals to the target areas in the organism(cells).

The ligand system may be enhanced by the production of an artificialsuper-oxide dismutase cycle and transported quickly through anextra-cellular process (especially Copper and Zinc) to cells. Thecomposition introduces the artificial SOD to a diseased tissue whereperoxide is produced (an oxygen production process) that will also aidin killing disease cells (e.g., cancer). The creation of the artificialSOD cycle causes the disease-causing organism to uptake an amount ofionic mineral that is toxic which results in death of the diseaseorganism. Additionally, diseases such as cancer follow an anaerobicfermentation process and oxygen will destroy the anaerobic fermentationprocess thereby providing a secondary mechanism for destroying thedisease. In certain embodiments, the composition may also contain sulfurthat may further aid in destroying cancer and provide relief of paincaused inflammation or other inflammatory-related diseases. The primemode of action are the mineral cations in a highly biologicallyavailable formulation carried by the ligand complex.

Other mineral formulations are not as bio-available and cannot passthrough cellular tissues in the manner demonstrated by the mineralcation hexa-aqua complex and ionic salt compositions described herein.In addition to the cationic mineral hexa-aqua complex and ionic saltcomposition, may further include predetermined amounts of at least oneof vitamins and botanicals. The vitamins and/or botanicals provide anextra measure for successful treatment of a disease or insuringwellbeing of the higher organism (e.g., cellular homeostasis).

The general principle of the mineral cation hexa-aqua complex and ionicsalt composition is rapid entry into the aerobic biological system of anorganism using a ligand carrier in an ionic form that penetrates andmigrates toward an anaerobic disease system, if present. The product iscapable of penetrating the barrier zone between the aerobic andanaerobic tissues if the disease is internal and usually encapsulated bya barrier consisting of mucous and a bacteria or virus. The uniquequality of the formulation is the penetration of tissues (cellmembranes) and the movement of large amounts of ionic content intointended cells. The accumulation of the large amounts of mineral becomestoxic to the anaerobic system and the disease-causing agents, infectedcells, or diseased are terminated.

Like other higher organisms, plants are subject to the same generalprincipals pertaining to the Krebs cycle. Again, the compositionpenetrates the membrane of the disease more readily than conventionalpreparations of minerals and the disease accumulates the mineral(s) to atoxic level, while surrounding healthy plant tissues are unaffectedexcept at extremely high dosages.

Diseases have three vulnerable sites that may be attacked by treatmentusing the mineral cation hexa-aqua complex and ionic salt compositionand methods described:

1. Penetrating the outer membrane of the pathogen, infected cell, ordiseased cell,2. Destroying the internal components that drive the cells metabolism,and3. Destroying the gene pool that may provide a future defense(resistance) against the introduced sub stance.

Minerals that are not in the bioavailable form will not be able toeliminate or otherwise disable the disease cells because the mineralscannot pass through the membrane coating the outer surface of thedisease and/or cannot travel extra-cellularly. The mineral cationhexa-aqua complex and ionic salt composition will attack all of thepathogen's vulnerable targets, as well as the infected or diseased cellsbecause of the systemic capabilities of the composition. The cellmembrane is easily traversed and possibly ruptured, the inner cell iscompromised because of the Kreb's cycle (aerobic vs. anaerobic) asdescribed above and the cell is rendered destroyed. Beyond destroyingthe pathogen, infected cell, or diseased cell, there will be no furtherdeviations from the genetic code to produce new strains of pathogenicagents or diseased cells that may be resistant to the product. In fact,there are no known resistances to animal and/or plant disease usingminerals as the primary source of treatment.

Mode of Operation

The mineral cation hexa-aqua complex and ionic salt composition usesionic mineral complexes and ionic salts that are capable of penetratingthrough the body having little to no adverse effect on normal cellswhile destroying the diseased or dysfunctional cells and pathogenicagents. Further, the ionic mineral complexes are capable of penetratingcell membranes at a rapid pace and are appropriately managed by normalcells as they will not allow net accumulation (abnormally highconcentration) of minerals, and are discharged as excessive withoutdisrupting normal cell functions. The action of the ligand or SODprovides for extra-cellular transport of the minerals to the pathogen,infected cell, or diseased cell, where mineral toxicity occurs. Theprocess of destruction of the pathogen, infected cells, or diseasedcells is an overload of mineral ions and in some cases the added effectof oxidation of the anaerobic disease fermentation process.

Normal cells will die as a result of excessive exposure to almost anymineral. The composition involves the use of an appropriate amount ofthe mineral in an ionic mineral complex form that will cause a toxiceffect to the pathogen, infected cell, or diseased cell while notreaching a toxic level in healthy cells.

Another mode of action examined as the possible method of destruction ofcancer and other diseases is the effect of the mineral cation complex onbacteria or other pathogens or saprophytic organisms that surround andact to encapsulate the disease. High numbers of bacteria, etc. have beenidentified in protective membranes and may be responsible for themembranes existence. The mineral cation hexa-aqua complex and ionic saltcomposition having anti-microbial properties and the ability to freelymove between and through cells is capable of reaching the interfacebetween healthy and diseased tissues and destroying the pathogenicagents. These properties may also be beneficial for penetratingprotective membranes found in other diseases (e.g., cancer).

The mineral cation hexa-aqua complex and ionic salt composition iscapable of destroying disease agents, and infected or diseased cells,wherein the body then removes said agents or cells (sheath like mass).The composition is capable of penetrating any sheath to the bacteria,and dissociate the sheath. The interior of the sheath contains thedisease or pathogen agent (including cancer) and the natural immunesystem, if intact, will reject the mass of cells contained in the sheathwhich may include bacteria, virus, or other disease-causing agentscontained within in a mass of cells that can move from an internal areaof the body to be expelled. The sheath is the mass created by theaccumulation of millions of white blood cells that accumulate around thedestroyed diseased tissue that are separated from healthy tissue at theinterface where the bacteria, virus, other disease agent was located.Once dead, the interface containing the destroyed disease agent,infected cells, or diseased cell and white-blood cells are separatedfrom the healthy tissue and the mass of tissue inside the sheath isexpelled from the body.

In certain embodiments, the compositions and formulations describedherein are formulated in a manner such that said compositions andformulations will be delivered to a cell in a therapeutically effectiveamount, as part of a prophylactic general health-supporting agent, apreventive agent, or a therapeutic treatment.

Examples of Diseases that May be Treated Using the Mineral CationHexa-Aqua Complex and Ionic Salt Composition

The mineral cation hexa-aqua complex and ionic salt composition does notperform in a biased nature toward any particular disease or pathogen.The mineral cation hexa-aqua complex and ionic salt composition allowsfor delivery of cationic minerals and ionic salts to cells of interest,wherein the cationic minerals and ionic salts traverse cellularmembranes depositing said ionic contents within cells. Numerouspathogens, and atypical pathologies (e.g., cancer), are known to alterthe physiology of the host cells, allowing for an environment amenablefor proliferation of said pathogen, or atypical pathology. The alteredphysiology can include a myriad of things including alteration of ionchannel function and general metabolism. Due to these alterations themineral cation hexa-aqua complex and ionic salt composition is able totraverse the cell membranes at a relatively high degree and dysregulatethe alterations made by the pathogen, or pathology, wherein the cell isunable to manage said ions (e.g., removal from the cell), resulting indeath of the host cell and/or pathogen. The disease-associatedalterations present in pathogen-effected, or atypical pathology-effectedcells, are not present in healthy unaffected cells; the mineral cationhexa-aqua complex and ionic salt composition may still permeate the cellmembrane of these cells, however these cells are able to appropriatelymanage these ions (e.g., removal from the cell), only allowing for netion delivery appropriate to maintain general function to healthy cells.In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may be used to prevent or treat viral diseases,bacterial diseases, protozoan diseases, and fungal diseases in a hostsubject. In other embodiments, the mineral cation hexa-aqua complex andionic salt composition may be used to destroy viral pathogens, bacterialpathogens, protozoan pathogens, and fungal pathogens outside of a hostsubject. In another embodiment, the mineral cation hexa-aqua complex andionic salt composition may be used to prevent or treat cancer in a hostsubject. In another embodiment, the mineral cation hexa-aqua complex andionic salt composition may be used to aid in tissue regeneration orwound healing. In another embodiment, the mineral cation hexa-aquacomplex and ionic salt composition may be used to provide stableinclusion of necessary ions to healthy cells. The mineral cationhexa-aqua complex and ionic salt composition effectively manages diseaseby not only directly disrupting disease (e.g., pathogen or atypicalpathology) present in a subject, but also maintains appropriatemetabolic homeostasis of healthy cells, allowing for optimallyfunctional metabolism, wherein a subject may be better suited to healwounds or fight diseases intrinsically.

Certain diseases and pathologies do not have a well-establishedtreatment or cure. Additionally, some diseases are difficult to identifyor diagnose and subsequently result in challenging progression anddifficult treatment. Several examples of these types of diseases arediscussed herein, and may be of particular interest for treatment usingthe mineral cation hexa-aqua complex and ionic salt composition.

The invention is now described with reference to treatment of thefollowing example diseases. These example diseases are provided for thepurpose of illustration only and the invention should in no way beconstrued as being limited to these particular disease examples, butrather should be construed to encompass any and all variations whichbecome evident as a result of the teaching provided herein.

Without further description, it is believed that one of ordinary skillin the art can, using the description provided herein, treat thefollowing illustrative example diseases using the mineral cationhexa-aqua complex and ionic salt composition. The following workingexamples, therefore, specifically point out the preferred embodiments ofthe present invention, and are not to be construed as limiting in anyway the remainder of the disclosure.

Lyme Disease

Lyme Disease is transmitted by the bite of various species of Ixodesticks carrying the etiologic agent, a pathogenic Borrelia bacterium (aspirochete). Organisms of the Borrelia burgdorferi sensu lato groupbelong to the family Spirochaetaceae, genus Borrelia. There are at least11 species in the B. burgdorferi complex and an unknown but large numberof substrains. At least three genospecies of the Borrelia burgdorferisensu lato group have been identified as pathogens: B. burgdorferi sensustricto, B. afzelli, and B. garinii. In addition, other species ofBorrelia have been implicated as being causative pathogenic agents. Themajor reservoir of the infection in the United States is the whitefooted mouse, and the infection can be transmitted to many mammalianspecies, including various other forms of wildlife, e.g. Easternchipmunks, dogs, cats, and humans.

Clinically, Lyme disease is a progressive disease with a wide array ofmanifestations. Early diagnosis and treatment is critical to preventprogression. Late disseminated infection can be associated withpermanent damage to the nervous and musculoskeletal systems. Unlike,most bacterial diseases that can be defined microbiologically by directobservation or culture of the pathogen, B. burgdorferi is difficult toculture or observe in clinical samples. Therefore, Lyme disease isdefined indirectly. Erythema migrans (EM) rash is the classic marker forthis infection at early stages. However, not all patients infected withpathogenic Borrelia develop EM. In the absence of EM, the current basisfor diagnosis is the demonstration of an and body response against apathogenic Borrelia in an appropriate clinical setting.

Sometimes Lyme disease can be cured with antibiotic treatment alone,especially when the treatment begins early in the course of illness.See, e.g., Tickhorne Diseases of the United States, A Reference Manualfor Health Care Providers, U.S. Dept. of Health and Human Services,Centers for Disease Control and Prevention, Fourth Edition, 2017;Cameron et al., Evidence Assessments and Guideline Recommendations inLyme Disease: the Clinical Management of Known Tick Bites, ErythemaMigrans Rashes and Persistent Disease, Expert Review of Anti-infectiveTherapy, Vol. 12, 9, 2014; Wormser et al., The Clinical Assessment,Treatment, and Prevention of Lyme Disease, Human GranulocyticAnaplasmosis, and Babesiosis: Clinical Practice Guidelines by theInfectious Diseases Society of America, Clinical Infectious Diseases,Vol. 43, Issue 9, Pages 1089-1134, November 2006; and, Conquering LymeDisease, Science Bridges the Great Divide, B. A. Fallon and J. Sotsky,Columbia University Press; Illustrated edition (Dec. 12, 2017), 456pages. Unfortunately, only a fraction of Lyme patients are being treateddue to equivocal clinical manifestations, inaccurate tests, andunderreporting.

Lyme disease, if left untreated, can result in a large range of signsand symptoms. Such signs and symptoms can include EM rashes, swollenlymph nodes, arthritis and swelling of joints, carditis and heartarrhythmia, neuritis, neurocognitive impairment, facial palsy,intermittent pain or paresthesia of the body, fever, fatigue, dizziness,and shortness of breath.

The result of undiagnosed and untreated patients can lead to thedevelopment of Post-Treatment Lyme Disease Syndrome (PTLDS), wheresymptoms persist for a duration of time even after treatment occurs.Furthermore, if left untreated the disease can progress to late-stagedevelopments such as chronic Lyme arthritis or chronic Lymeneuroborreliosis, which can have devastating consequences in certaincases.

Due to difficulty in diagnosis and early treatment, there is clearly aneed for reliable treatment for those that have been infected with LymeDisease as well as those who may contract Lyme Disease.

COVID-19

A new disease called coronavirus disease 2019 (COVID-19) recentlyemerged globally (Centers for Disease Control (CDC), 2020). COVID-19illnesses have ranged from mild symptoms to severe illness and death.The World Health Organization declared the outbreak a Public HealthEmergency of International Concern on 30 Jan. 2020, and a pandemic on 11March 2020. As of 10 July 2020, over 12 million cases of COVID-19 (inaccordance with the applied case definitions and testing strategies inthe affected countries) have been reported, including over 500,000deaths.

COVID-19 is caused by a strain of coronavirus called severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 waspreviously referred to by its provisional name, 2019 novel coronavirus(2019-nCoV), and has also been called human coronavirus 2019 (HCoV-19 orhCoV-19).

SARS-CoV-2 is a positive-sense, single-stranded RNA virus that iscontagious in humans. Taxonomically, SARS-CoV-2 is a strain of severeacute respiratory syndrome-related coronavirus (SARS-CoV). It isbelieved to have zoonotic origins and has close genetic similarity tobat coronaviruses, suggesting it emerged from a bat-borne virus. Thevirus shows little genetic diversity, indicating that the spilloverevent introducing SARS-CoV-2 to humans is likely to have occurred inlate 2019.

Epidemiological studies estimate that each COVID-19 infection results in1.4 to 3.9 new ones when no members of the community are immune and nopreventive measures taken. The virus is thought to primarily spreadbetween people through close contact and via respiratory dropletsproduced from coughs or sneezes. It mainly enters human cells by bindingto the receptor angiotensin converting enzyme 2 (ACE2).

Signs and symptoms of COVID-19 may range from fever, shortness of breathor difficulty breathing, fatigue, muscle or body aches, headache, lossof taste or smell, sore throat, congestion, nausea or vomiting,diarrhea, to respiratory failure, and death.

No vaccine or cure for COVID-19 currently exists. Treatments continue todevelop with only varying success. Given the high rate of infectivityand mortality associated with SARS-CoV-2, there is clearly a need forreliable treatment for those that have been infected with SARS-CoV-2 aswell as those who may contract COVID-19.

Hepatitis C

Infection by hepatitis C virus (HCV) is a compelling human medicalproblem. HCV is recognized as the causative agent for most cases ofnon-A and non-B hepatitis, with an estimated worldwide prevalence of 170million cases as of the mid 1990s (i.e., 2-3%) (Choo et al., Science,1989, 244:359-362; Kuo et al., Science, 1989, 244:362-364; Purcell,PEDIS Microbiol. Rev., 1994, 14:181492; Van der Poel, In: CurrentStudies in Hematology and Blood Transfusion, Reesink ed., Basel: Karger,pp. 137-163, 1994).

HCV is primarily transmitted parenterally, although sexual and perinataltransmission do appear to occur. At present, no risk factor has beenidentified in about 40% of HCV-infected individuals in the US (Alter,Infect. Agents Dis., 1993, 2:155-166). Upon first exposure to HCV, onlyabout 10% or less of infected individuals develop acute clinicalhepatitis, while others appear to resolve the infection spontaneously.In most instances, however, the virus establishes a chronic infectionthat persists for decades, leading in about 50% of all cases to chronichepatitis, which can, in turn, develop into liver cirrhosis and/orhepatocellular carcinoma (Iwarson, FEMS Microbiol. Rev., 1994,14:201-204; Kew, ibid. pp. 211-220; Saito et al., Proc. Natl. Acad. Sci.USA, 1990, 87:6547-6549).

Apart from liver cells, HCV can also replicate in peripheral bloodmononuclear cells (PBMCs) both in vivo and in experimentally infected B-and T-cell lines (U.S. Pat. Nos.: 5,679,342 and 5,968,775). Such alymphotropism may account for the numerous immunological disorders, inparticular type II and type III cryoglobulinaemia, observed in more than50% of chronic hepatitis C patients (Esteban et al., In: Hepatitis CVirus, Reesink ed., Basel: Karge, 1998, pp. 102-118).

Signs and symptoms of hepatitis C range from bleeding and bruisingeasily, fatigue, poor appetite, yellow discoloration of the skin andeyes (jaudice), dark-colored urine, itchy skin, fluid buildup in theabdomen (ascites), swelling in legs, weight loss, confusion and slurredspeech (hepatic encephalopathy), and spider angiomas, to liver failureand death.

Unlike hepatitis A and hepatitis B, currently there is no vaccine forhepatitis C. Hepatitis C treatment commonly involves using anti-viralmedication. Given that acute hepatitis C infection usually goesundiagnosed, due to often asymptomatic presentation, there is clearly aneed for reliable treatment for those that have been infected withhepatitis C as well as those who may contract hepatitis C.

African Swine Fever

African swine fever is a haemorrhagic disease of domestic pigs caused bya double-stranded DNA virus, African swine fever virus (ASFV). ASFV isthe only member of the Asfarviridae fa oily and replicates predominantlyin the cytoplasm of cells. Virulent strains of ASFV can kill domesticpigs within about 5-14 days of infection with a mortality rateapproaching 100%.

ASFV can infect and replicate in warthogs (Phacochoerus sp.), bushpigs(Potamocherus sp.) and soft ticks of the Ornithodoros species, but inthese species few if any clinical signs are observed and long termpersistent infections can be established. The disease is currentlyendemic in many sub-Saharan countries and in Europe in Sardinia.Following its introduction to Georgia in the Trans Caucasus region in2007, ASFV has spread extensively through neighboring countriesincluding the Russian Federation. In 2012 the first outbreak wasreported in Ukraine and in 2013 the first outbreaks in Belarus. In 2014further outbreaks were reported in pigs in Ukraine and detection in wildboar in Lithuania and Poland.

There is currently no treatment for ASF. Prevention in countries outsideAfrica has been attempted on a national basis by restrictions onincoming pigs and pork products, compulsory boiling of waste animalproducts under license before feeding to pigs and the application of aslaughter policy when the disease is diagnosed. Prevention in Africa isbased on measures to keep warthogs and materials contaminated bywarthogs away from the herd. Thus, there is thus a need for improvedmeasures to control ASFV infection and prevent spread of the disease.

Cancer

Cancer is a disease, characterized by the development of abnormal cellsthat exhibit uncontrollable proliferation and the ability to permeateand damage normal body tissues. Cancer is notable for being one of theleading causes of death worldwide.

Signs and symptoms of cancer vary widely, often negatively influencingthe function of the particular tissues the aberrant cells infiltrate.

Unfortunately, a cure for cancer has yet to be identified, however anumber of various treatments do exist. Thus, a need for additionalmeasures are needed to aid in cancer treatment or prevention.

Wound Management

Tissues often experience degrees of damage through various means (e.g.,general wear and tear, trauma, surgical intervention). Tissueregeneration requires the physiological ability for cells toappropriately proliferate and return functionality to an affected area.Cells must undergo assimilate partitioning to correctly manifest newtissue, wherein nutrients and resources are appropriately allocated tocells to perform needed function (e.g., cellular respiration, proteinmetabolism, and nucleic acid metabolism). Thus, if a subject is lackingappropriate nutrients and resources, cells are at a disadvantage toregenerate tissues.

Not only can normal tissue regeneration and wound management be adifficult task, but it can also be exacerbated by complications thateasily manifest during healing making treatment even more difficult.Such complications include, infection, osteomyelitis, tissue necrosisand gangrene; periwound dermatitis, edema and periwound edema,hematomas, and dehiscence which can result in chronic non-healingwounds. Treatment of wounds can often include treatment of secondarycomplications, vacuum granulation of tissue; dssue scaffolding, grafttissues, surgical intervention, haemoglobin spray, and hyperbaric oxygentherapy, to name a few. Thus, a need for additional measures are neededto aid in wound management.

Disease Mitigation by Application of the Composition

Due to the mineral cation hexa-aqua complex and ionic salt compositionmode of action, non-toxic nature on higher organisms, and ability tosolubilize in water, the composition may be used as an agent thatprevents the accumulation of, or mitigates, pathogens in an ex-vivocapacity. Contacting the mineral cation hexa-aqua complex and ionic saltcomposition with elements of the terrestrial environment, objects, orcommercial foods may be an effective way in which to kill or render apathogenic agent ineffective.

The mineral cation hexa-aqua complex and ionic salt composition of thepresent invention can be dfective against pathogens in water and may beused at rates that are effective against higher organism pathogens.Post-harvest drenches of the product on fruits, vegetables, animalby-products, milk, eggs, poultry and other articles have been shown toharbor pathogens. In certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition may be used to reduce or eliminatepathogens from post-harvest drenches. The compositions of the presentinvention may be capable of eliminating pathogens that threaten bothanimals and plants.

The mineral cation hexa-aqua complex and ionic salt composition may alsobe effective in reducing and/or eliminating pathogens that result duringstorage and handling of fish, shellfish, poultry, meat products ofcattle, sheep, pigs and other animals. In certain embodiments, rinsing,dipping and/or washing, or by other means of treatment, of animalproducts using the mineral cation hexa-aqua complex and ionic saltcomposition may provide control and/or elimination of pathogens thataffect higher organisms. The mineral cation hexa-aqua complex and ionicsalt composition of the present invention may be effective incontrolling and/or eliminating pathogens such as pathogenic bacteria,virions, fungi, protozoans and other diseases or pathogens of importanceto the health of higher organisms when used in a similar manner.

The mineral cation hexa-aqua complex and ionic salt composition may beeffective in controlling and/or eliminating storage pathogens in liquidssuch as, but not limited to, water, juices, milk, etc. in certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may be used to wash and coat, or by other means oftreatment, food and non-food products, wherein the shelf life of saidproducts may be extended by eliminating the storage diseases while notaffecting the food and nonfood products.

In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may be applied to animal and/or plant by-products suchas water, milk, and milk by-products, juices and other liquids used inhuman and animal consumption to destroy pathogens and enhance foodsafety.

Furthermore, in certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition and formulations thereof may be usedto kill or destroy a pathogenic agent on environmental surfaces.

The mineral cation hexa-aqua complex and ionic salt composition can beused in aerosolized, misted, vaporized, fogged, humidified or otherforms to produce micronized particles of the composition that can remainin suspension in the air for long periods of time. The micronizedparticles a.ct much like a fumigant to provide total coverage to allsides of a surface that may be harboring pathogenic agents. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition, in any form, may be able to intercept pathogenic agents(e.g., protozoans, bacteria, fungi, viruses), spores and/or resting(dormant) stages of pathogens in the air or on a surface, wherein saidpathogenic agents are rendered ineffective. In certain embodiments, themineral cation hexa-aqua complex and ionic salt composition prompts thepathogen to vegetate and/or otherwise vitalize the dormant stage,wherein the mineral cation hexa-aqua complex and ionic salt compositionby itself or in combination with other components of a formulationcapable of killing or rendering ineffective the vegetative stage and/orspores and/or resting spores and/or resting stage of a pathogen bycontact and/or action of the composition on the pathogen.

In certain embodiments, the formulation of the mineral cation hexa-aquacomplex and ionic salt composition includes inert ingredients such as,but not limited to surfactants, detergents or semiochemicals that mayfurther affect the dormant stage of pathogens by acting on the cellwalls or structure of the pathogen allowing the composition to kill themost resistant life stage of the pathogen. For example, the cell walk ofbacteria or fungal spore are hydrophilic (attract and absorb water). Incertain embodiments, the mineral cation hexa-aqua complex and ionic saltcomposition deployed in a micronized mist (which contains water) isattracted to the structure of the fungus and bacillus and may be furthercompromised through the use of surfactants; detergents and/orsemiochemicals, wherein the composition of the present invention is thenable to kill or render ineffective the pathogenic agent. If bacterialspores or resting spores are coated with a hydrophilic material (such asgelatin) target pathogenic agents may be further encapsulated andenhance treatment using the mineral cation hexa-aqua complex and ionicsalt composition. In certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition may be applied to resting sporesand/or to cell walls of the bacterium by mist using a hydrophiliccoating, wherein the pathogen may be further compromised allowing thecomposition kill or render the pathogen agent ineffective.

The micronized particle may be used in any situation where air-bomepathogenic fungal spores and/or other vegetative or reproductive stagesof pathogens are present. The composition of the present invention maytherefore be used to eradicate highly refined pathogenic agentsincluding animal and plant air-borne pathogens.

Additives to Composition

In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may be formulated in combination with inerts that mayinclude, but are not limited to additives such as surfactants, di-methyl sulfoxide (DSMO), detergents, hydroscopic compounds such as, butnot limited to Cell-U-Wet, and/or other chemicals, to aid in penetrationthrough the skin and/or for other reasons necessary in manufacture offormulations for ingestion, inhalation, injection, tablets, suppository,transdermal patches, etc.

Nebulization Formulation

In some embodiments, the composition is formulated to be administeredthrough inhalation via nebulization or dispersed in droplet form.Formulation suitable for nebulization presents as an effective route ofadministration for delivery to the respiratory tract. This mechanism ofdelivery may be particularly helpful in combating novel respiratorydiseases as well as functions as a quick acting systemic delivery routefor the mineral cation hexa-aqua complex and ionic salt composition.

It should be noted that this is this an effective route of systemicadministration, but is particularly useful for treatment of pathogens,infected cells, and diseased cells associated with the pulmonary system.

In some nebulizers, a gas and a fluid are mixed together and directedagainst a baffle or diverter. In some other nebulizers, interaction ofthe gas and fluid is enhanced through impacting the gas and fluidagainst a diverter. The term diverter, as used here, includes any baffleor impinger. As a result of either nebulization process described above,the fluid is transformed into an aerosol, that is, the fluid is causedto form small particles that are suspended in the air and that have aparticle size in a range suitable for delivery to a targeted area of apatient's respiratory tract. One way to mix the gas and fluid togetherin a nebulizer is to pass a quickly moving gas over a fluid orifice tipof a tube. The negative pressure created by the flow of pressurized gasis a factor that contributes to drawing fluid out of the fluid orificeinto the stream of gas and nebulizing it.

Effective and economical nebulizer therapy includes the ability toquickly generate a large amount of aerosol within a predeterminedparticle size range. An effective nebulizer preferably provides thesefeatures synchronously with the inhalation of the patient. In order toactuate a mechanical nebulizer, a patient's inhalation effort mustovercome certain variables. Depending on the structural configuration ofthe nebulizer, these variables may include one or more of the following:the volumetric flow rate of the flowing gas; air leaks in the device;the force exerted by the flowing gas on a moveable diverter; and thefriction between moveable parts. The greater the flow rate, air leaksand friction, the greater the inhalation effort required in order toactuate the device. It is desirable that a nebulizer have adequatesensitivity to quickly respond to an inhalation while not adverselyrestricting the patient's inhalation.

Various excipients and carriers may be used to increase effectivedelivery of nebulized therapeutics. Depending on the mechanism of actionfor nebulization and the components of the therapeutic, the use oftonicity adjusting agents, pH adjusting agents, buffering agents,purging agents, co-solvent agents, antimicrobial preservative agents,suspension agents, surfactant agents, and humectant agents can bewarranted.

Agents specifically intended for nebulization may include one or more oftonicity adjusting agents including sodium chloride, and dextrose; pHadjusting agents including sodium hydroxide, hydrochloric acid, andsulphuric acid; buffering agents including sodium citrate, sodiumphosphate, and citric acid; purging agents including nitrogen;co-solvent agents including alcohol, polyethylene glycol (PEG) 400, andpropylene glycol; antimicrobial preservative agents includingbenzalkonium chloride, ethanol, propylene glycol, beczoyl alcohol,chlorobutanol, and methyl paraben; suspension agents includingcarboxymethylcellulose (CMC), and sodium CMC; surfactant agentsincluding poractant, poracant alfa, polysorbate 80 and polysorbate 20;and humectant agents including glycerin. In certain embodiments, themineral cation hexa-aqua complex and ionic salt composition may beformulated to be administered via nebulization or by droplet dispersionby including one or more of tonicity adjusting agents including sodiumchloride, and dextrose; pH adjusting agents including sodium hydroxide,hydrochloric acid, and sulphuric acid; buffering agents including sodiumcitrate, sodium phosphate, and citric acid; purging agents includingnitrogen; co-solvent agents including alcohol, polyethylene glycol (PEG)400, and propylene glycol; antimicrobial preservative agents includingbenzalkonium chloride, ethanol, propylene glycol, beczoyl alcohol,chlorobutanol, and methyl paraben; suspension agents includingcarboxymethylcellulose (CMC), and sodium CMC; surfactant agentsincluding poractant, poracant alfa, polysorbate 80 and polysorbate 20;and humectant agents including glycerin. In other embodiments, themineral cation hexa-aqua complex and ionic salt composition may beformulated to be administered via nebulization or by droplet dispersionby not incorporating a tonicity adjusting agent, pH adjusting agent,buffering agent, purging agent, co-solvent agent, antimicrobialpreservative agent, suspension agent, surfactant agent, or humectantagent.

Botanical Extracts and Isolations

Plants, plant extracts and isolations have been used for centuries totreat certain diseases in humans and promote general wellness. One majorfactor in the cure of diseases and wellness is boosting the immunesystem and, several plants are known to have ingredients that have shownsupport in helping to fight or prevent disease. The mineral ion zinc,may be used in coordination with certain plant extracts for boosting theimmune system and combating certain diseases. For example, extracts mayinclude any of the following but are not limited to: Graviola (Annonamuricata), Bitter Melon (Momordica charantia), Esplanheira Santa(Maytenus illcifolia), Mullaca (Physolis angulata), Vasourinho (Scopariadulcis), Mutamba (Guazuma ulmifolia), Suma (Pfaffia paniculata), Cat'sClaw (Uncaria tomantosa), Blood Root (Sanguinaria canadensis). Thequality of the botanical correlates to the performance of the plantextracts and a person trained in the art is necessary in most cases toprovide a measure of success.

For example, not all Graviola trees will yield the same amount of theactive ingredient from the leaves or fruit, and someone skilled inselection of the leaves from specific trees can provide a superiorextract following a detailed recipe. For instance, only bottled water(not chlorinated) must be mixed with a specific surfactant before addingcinnamon and the plant material and cooked in stainless steel or glassfor five days at 140-160 degrees F. and twice filtered before storage atroom temperatures and in some embodiments the product is not taken withco-enzyme Q1O (C0Q10). Q10 which is a food supplement. The results arenoteworthy when with the mineral cation hexa-aqua complex and ionic saltcomposition and other supplements including but not limited to vitaminsand minerals.

Vitamin and Mineral Supplements

The use of mineral cation hexa-aqua complex and ionic salt compositionmay greatly improve general health, but not all minerals can beprocessed into a mineral cation hexa-aqua complex and ionic saltcomposition. Therefore, mineral supplements may be necessary intraditional forms to meet minimum daily requirements when boosting thestrength of the immune system. It is true that the daily allowances forboth vitamins and minerals can be obtained through a healthy diet, butwhen an individual's immune system is compromised and they are facingdisease (e.g., cancer or some other major disease), supplementing thefood intake is critical to the mitigation of the disease, or appropriateresponse and maintenance of the disease.

An example of a rigorous and effective regimen of vitamins and mineralsfor establishing cellular homeostasis and optimum functionality, but isnot limited to the following:

MORNING

Beta Carotene (Vit. A)—25,000 LU.Vit. B-6—100 mgCOQ 10 (Except with Graviola)—100 mg

Folic Acid—800 mg

Vit. D—400 LU.

Selenium (Yeast)—200 mcg Biotin—1000 mcg Chromium Piconate—200 mcg

Multi-Vitamin (Organic) that contains Micro-Nutrients (Trace Elements)

EVENING

Aspirin (If Tolerant)—small (e.g., 75 to 150 mg)

Zinc Gluconate—250 mg Magnesium Sterate—250 mg Calcium Citrate—600 mgOmega 3 (Fish Oil)—1000 mg Red Yeast Rice—600 mg

Vit. E—400 LU.Ester Vit. C—1000 mg

Glucosamine Sulfate—500 mg Chondrotin Sulfate—500 mg

Methyl sulfonylmethane—200 mg

The efficacy of the mineral cation hexa-aqua complex and ionic saltcomposition may be enhanced by using the composition in combination withbotanicals and vitamins. In certain embodiments, use of botanicals andvitamins may be used in combination with mineral cation hexa-aquacomplex and ionic salt composition to synergistically impact anorganisms own cellular function manage infection and disease while alsomaintaining healthy cells. The mineral cation hexa-aqua complex andionic salt composition provides a direct attack on the membrane sheathsurrounding the cancer cells and a direct attack on the cancer itself byover-loading the cancer cells with minerals that become toxic to thecancer while not affecting the surrounding healthy tissues.

Modifications

The treatment of diseases such as cancers, for example, skin, colon,liver, prostate cancer may require different combinations of the ionicmineral complexes formulated with certain inerts and made for eachspecific application. In certain embodiments, the mineral cationhexa-aqua complex and ionic salt composition may also containpharmaceutically acceptable carriers, diluents, cream bases, hydroscopicadditives, detergents and/or other carriers required for thetherapeutically effective dosage to travel to the specific target sitefor the intended purpose. In certain embodiments, mineral cationhexa-aqua complex and ionic salt composition may be therapeuticallyadministered by at least one of topical, oral, inhalation, injection,rectally or other methods of application, in a therapeutically effectiveform of the formulation. Other diseases that can be mitigated by use ofmineral cation complexes by themselves or in combinations of mineralcation complexes derived from the method of disassociation of compoundsinclude, but are not limited to, arthritis or any other degenerativedisease. The same systems of ionic minerals can be used for promotingwellness of an individual to facilitate disease resistance, increaseenergy, etc. Formulations for applying the active ingredient(s) include,but are not limited to, the above inert ingredients.

The mineral cation hexa-aqua complex and ionic salt composition may betailored to incorporate various ionic materials that may be directed toenhance or treat dysfunctional innate biological functions. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise calcium to be used to positively influence ortreat dysfunction associated with bone and tooth development, enzymeactivity, blood pressure regulation, muscle contraction, neuronalsignaling, and blood clotting. In certain embodiments, the mineralcation hexa-aqua complex and ionic salt composition may comprise carbonto be used to positively influence or treat dysfunction associated withmacromolecule formation or metabolism in biological systems. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise chloride to be used to positively influence ortreat dysfunction associated with fluid regulation, blood pressure, andpH regulation. In certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition may comprise chromium to be used topositively influence or treat dysfunction associated with blood sugarregulation, and carbon metabolism. In certain embodiments, the mineralcation hexa-aqua complex and ionic salt composition may comprise cobaltto be used to positively influence or treat dysfunction associated withcell division, amino acid synthesis, and co-enzyme functionality. Incertain embodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise copper to be used to positively influence ortreat dysfunction associated with general metabolism, red blood cellformation, neurotransmitter regulation, and reduction of free radicals.In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may comprise fluoride to be used to positivelyinfluence or treat dysfunction associated with bone and tooth structuralmaintenance. In certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition may comprise iron to be used topositively influence or treat dysfunction associated with red blood cellfunctionality, amino acid synthesis, collagen synthesis,neurotransmitter synthesis, and hormone synthesis. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise hydrogen to be used to positively influence ortreat dysfunction associated with plays a role in things such asformation and structure of macromolecules, and metabolic functionality.In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may comprise iodine to be used to positively influenceor treat dysfunction associated with hormone synthesis and generalmetabolism. In certain embodiments, the mineral cation hexa-aqua complexand ionic salt composition may comprise nitrogen to be used topositively influence or treat dysfunction associated with amino acidsynthesis. In certain embodiments, the mineral cation hexa-aqua complexand ionic salt composition may comprise magnesium to be used topositively influence or treat dysfunction associated with bone and toothdevelopment, blood pressure regulation, muscle contraction, neuronalimpulses, blood clotting, and enzyme functionality. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise manganese to be used to positively influence ortreat dysfunction associated with amino acid metabolism, cholesterolmetabolism, and carbohydrate metabolism. In certain embodiments, themineral cation hexa-aqua complex and ionic salt composition may comprisemolybdenum to be used to positively influence or treat dysfunctionassociated with enzyme functionality, and removal of toxins. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise nickel to be used to positively influence ortreat dysfunction associated with enzyme functionality and red bloodcell maintenance. In certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition may comprise oxygen to be used topositively influence or treat dysfunction associated with signaling,metabolism, and cellular respiration. In certain embodiments, themineral cation hexa-aqua complex and ionic salt composition may comprisephosphorous to be used to positively influence or treat dysfunctionassociated with bone and tooth development, carbohydrate and lipidmetabolism, and growth/maintenance and development. In certainembodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise potassium to be used to positively influence ortreat dysfunction associated with regulating fluids, maintain myocardialcontractions, and general muscle contraction. In certain embodiments,the mineral cation hexa-aqua complex and ionic salt composition maycomprise silicon to be used to positively influence or treat dysfunctionassociated with collagen and elastin synthesis for development andmaintenance of connective tissue. In certain embodiments, the mineralcation hexa-aqua complex and ionic salt composition may compriseselenium to be used to positively influence or treat dysfunctionassociated with hormone regulation, nucleic acid synthesis, and cellulardefense. In certain embodiments, the mineral cation hexa-aqua complexand ionic salt composition may comprise sodium to be used to positivelyinfluence or treat dysfunction associated with regulating fluids,neuronal impulses, and muscle contraction. In certain embodiments, themineral cation hexa-aqua complex and ionic salt composition may comprisesulfur to be used to positively influence or treat dysfunctionassociated with protein synthesis, and antioxidant production. Incertain embodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise vanadium to be used to positively influence ortreat dysfunction associated with immune response and growth factors. Incertain embodiments, the mineral cation hexa-aqua complex and ionic saltcomposition may comprise zinc to be used to positively influence ortreat dysfunction associated with amino acid and nucleic acidbiosynthesis, immune system functionality, and cellular division.

Complex Ion Formation/Ligand Bonds

The formation of the hexa-aqua complex is understood in chemistry ascomplex ion formation. The mineral cation acts as a central ion, wheremolecules attach to the central metal ion to form a complex. Thesemolecules attaching to the central metal ion are considered ligands,wherein the ligands supply electrons by means of coordinate covalentbonding. Examples of simple ligands include water, ammonia, and chlorideions.

Ligands function as lone pair donors, and thus Lewis bases. Centralmetal ions that form a number of bonds with the ligands determine thecoordination number, or total points of attachment to the centralelement, for the complex ion. Therefore, hexa-aqua complexes are metalaquo complexes using only water as a ligand forming six coordinatecovalent bonds with a central metal ion.

The mineral cation hexa-aqua complex and ionic salt compositionmanufacturing process produces a complex having ammonia ligand bondswith specific cations. The cations are “encapsulated” by the ligandbonds and are protected from being immediately bonded with the firstavailable negative ions thus enabling free movement between and withincells of the body. Each of the minerals will be processed in anacid-base solution, resulting in products that have a high acidityvalue, yet not being corrosive to living tissue. A high concentration ofreactive ammonia is also produced by the acid-base reaction. Complexcations and inorganic coordination complexes are formed that are able to“encapsulate” the cations in a relatively stable fashion and allowtransport throughout the body.

A method for producing a mineral cation hexa-aqua complex and ionic saltcomposition for treating and mitigating disease while also bolsteringmetabolic homeostasis of healthy cells, comprising forminghexa-coordinated complexes with one or more cationic minerals bydissolving one or more ionic salts in water, wherein the compositioncomprises at least one cationic mineral complex encapsulated byhexa-aqua ligands. In some embodiments, amines attached to metal ionswhich are slowly absorbed as the ligand structure moves toward waterligands establishing a hexa-aqua complex and freeing up the amines forassimilation along with other antioxidants including hydrogen, andsulfur and nitrogen salts. In certain embodiments, other formulationsmay include other salts that comprise phosphorous, nitrogen, potassium,sodium, chloride, calcium, and/or bicarbonate in combination with othermetals. A prepared mixture includes at least one organic mineral complexencapsulated by hexa-aqua ligands. In some embodiments, the one or morecationic minerals comprise chromium, cobalt, copper, gold, iron,manganese, magnesium, molybdenum, nickel, platinum, silver, vanadium,and zinc. In some embodiments, the one or more ionic salts comprisenitrogen, phosphorous, potassium, sulfur, and hydrogen. In certainembodiments, a diluted mixture may be combined with a pharmaceuticallyacceptable carrier for delivery with other ingredients.

In some embodiments, preparing the composition includes generating asolution of ammonium hydrogen sulfate using sulfuric acid (without pHbuffering), diluting the ammonia hydrogen sulfate with water to form amixture; adding specific minerals from the designated selection to themixture in a salt form; and agitating the mixture comprising theammonium hydrogen sulfate, sulfuric acid, water, and the mineral saltingredients. In certain embodiments, other salts may be incorporated inthe beginning formulation, or other formulations, with other mineralsutilizing the basic concept as described above with substitution of thesalt preparation.

In some embodiments, generating a solution of ammonium hydrogen sulfatecomprises in the following order, a) mixing ammonium sulfate withdistilled water; and b) mixing sulfuric acid with the mixture comprisingammonium sulfate and distilled water, wherein the components of saidmixture are added at a rate that does not result in an exothermicreaction in excess of 300° C. during either a) or b).

In some embodiments, the concentration of ammonium sulfate used ingenerating the solution of ammonium hydrogen sulfate is about 20% w/v orless. In some embodiments, the concentration of ammonium sulfate used ingenerating the solution of ammonium hydrogen sulfate is about 1%, 2%,3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,19%, or 20% w/v. In some embodiments, the concentration of ammoniumsulfate used in generating the solution of ammonium hydrogen sulfate isbetween about 1% w/v and about 20% w/v. In some embodiments, theconcentration of ammonium sulfate used in generating the solution ofammonium hydrogen sulfate is between about 1% w/v and 5% w/v. In someembodiments, the concentration of ammonium sulfate used in generatingthe solution of ammonium hydrogen sulfate is between about 5% w/v and10% w/v. In some embodiments, the concentration of ammonium sulfate usedin generating the solution of ammonium hydrogen sulfate is between about15% w/v and 20% w/v. In some embodiments, the concentration of ammoniumsulfate used in generating the solution of ammonium hydrogen sulfate isgreater than about 20% w/v.

In some embodiments, the ammonium sulfate used in generating thesolution of ammonium hydrogen sulfate is mixed with distilled water at aratio between about 9:1 and about 1:15, between about 5:1 and about1:10, between about 3:1 and about 1:5, including all ratios in between,e.g., about 3:1, about 3:2, about 2:1, about 1:2, about 1:3, about 1:4,about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10,ammonium sulfate to distilled water. In some embodiments, the ammoniumsulfate used in generating the solution of ammonium hydrogen sulfate ismixed with distilled water at a ratio of 3:2 or less, ammonium sulfateto distilled water. In some embodiments, the ammonium sulfate used ingenerating the solution of ammonium hydrogen sulfate is mixed withdistilled water at a ratio of 1:1 or less, ammonium sulfate to distilledwater.

In some embodiments, the concentration of sulfuric acid used ingenerating the solution of ammonium hydrogen sulfate is about 18 M. Insome embodiments, the sulfuric acid used in generating the solution ofammonium hydrogen sulfate is mixed with the mixture comprising ammoniumsulfate and distilled water at a ratio between about 9:1 and about 1:15,between about 5:1 and about 1:10, between about 3:1 and about 1:5,including all ratios in between, e.g., about 3:1, about 3:2, about 2:1,about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about1:8, about 1:9, about 1:10, sulfuric acid to mixture comprising ammoniumsulfate and distilled water. In some embodiments, the sulfuric acid usedin generating the solution of ammonium hydrogen sulfate is mixed withthe mixture comprising ammonium sulfate and distilled water at a ratioof 1:1 or more, sulfuric acid to mixture comprising ammonium sulfate anddistilled water. In some embodiments, the sulfuric acid used ingenerating the solution of ammonium hydrogen sulfate is mixed with themixture comprising ammonium sulfate and distilled water at a ratio of2:1 or less, sulfuric acid to mixture comprising ammonium sulfate anddistilled water.

In some embodiments the mixture comprising ammonium sulfate, distilledwater, and sulfuric acid is cooled to a temperature between about 5° C.and about 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature between about 10° C. andabout 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature between about 20° C. andabout 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature between about 30° C. andabout 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature between about 40° C. andabout 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature between about 50° C. andabout 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature between about 60° C. andabout 70° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature of less than about 70° C.prior to adding one or more cationic minerals. In some embodiments themixture comprising ammonium sulfate, distilled water, and sulfuric acidis cooled to a temperature of less than about 65.5° C. prior to addingone or more cationic minerals. In some embodiments the mixturecomprising ammonium sulfate, distilled water, and sulfuric acid iscooled to a temperature of less than 65.5° C. prior to adding one ormore cationic minerals. In some embodiments the mixture comprisingammonium sulfate, distilled water, and sulfuric acid is cooled to atemperature of less than 60° C. prior to adding one or more cationicminerals. In some embodiments the mixture comprising ammonium sulfate,distilled water, and sulfuric acid is cooled to a temperature of lessthan 50° C. prior to adding one or more cationic minerals. In someembodiments the mixture comprising ammonium sulfate, distilled water,and sulfuric acid is cooled to a temperature of about 5° C., 10° C., 20°C., 30° C., 40° C., 50° C., 60° C., or 70° C. prior to adding one ormore cationic minerals.

In some embodiments, the one or more cationic minerals are added to themixture so that the ratio of minerals is optimized for bioavailabilityand avoidance of adverse mineral interactions of a biological system. Insome embodiments, the one or more cationic minerals are added to themixture of ammonium sulfate, distilled water, and sulfuric acid at ratiobetween about 9:1 and about 1:15, between about 5:1 and about 1:10,between about 3:1 and about 1:5, including all ratios in between, e.g.,about 3:1, about 3:2, about 2:1, about 1:1, about 1:2, about 1:3, about1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10,of any of the one or more cationic minerals to one and other. In someembodiments, the one or more cationic minerals are added to the mixtureof ammonium sulfate, distilled water, and sulfuric acid at ratio of atleast 1:1:1, wherein the one or more cationic minerals are zinc, copper,and magnesium. In some embodiments, the one or more cationic mineralsare added to the mixture of ammonium sulfate, distilled water, andsulfuric acid at a ratio of no more than 3:1:1, wherein the one or morecationic minerals are zinc, copper, and magnesium.

In some embodiments, the one or more cationic minerals are added to themixture with one or more stabilizing materials. In some embodiments, theone or more cationic minerals are added to the mixture without one ormore stabilizing materials. As used herein, a “stabilizing material” isany substance that may be used to preserve chemical and/or physicalproperties of a material to prevent degradation or unintendedinteraction. Stabilizing materials may operate inversely to that of acatalyst. Representative examples of stabilizing materials include, butare not limited to, antioxidants, sequestrants, ultraviolet stabilizers,emulsifiers, surfactants, thickeners and gelling agents, humectants,anticaking agents, coating agents, corrosion inhibitors, and inertelements.

In some embodiments of the method of producing the composition of thedisclosure, the method further comprises combining the composition witha pharmaceutically acceptable carrier.

In some embodiments of the method of producing the composition of thedisclosure, the method further comprises combining the composition withone or more botanical agent(s). In some embodiments, the one or morebiological agent(s) comprises Graviola (Annona muricate), Bitter Melon(Momordica charantia), Esplanheira Santa (Maytenus illcifolia), Mullaca(Physolis angulate), Vasourinho (Scoparia dulcis), Mutamba (Guazumaulmifola), Suma (Pfaffia paniculata), Cat's Claw (Uncaria tomantosa) andBlood Root (Sanguinaria canadensis).

Composition Permutations

A composition for treating and mitigating diseases, while alsobolstering cellular metabolic functionality includes a therapeuticallyeffective amount of a mineral cation hexa-aqua complex and ionic salt ina pharmaceutically acceptable carrier (the mineral cation hexa-aquacomplex and ionic salt composition). The cationic mineral, or minerals,are bound in a hexa-aqua complex enabling transport of said ionicmineral through a biological system to a target cell.

In certain embodiments, the mineral cation of the mineral cationhexa-aqua complex and ionic salt composition may be at least one of, orany combination of, actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be actinium, andat least one of bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form metal aquo complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be bohrium, and at least one of actiniumcadmium, chromium, cobalt, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form metal aquo complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe cadmium, and at least one of actinium, bohrium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be chromium, andat least one of actinium, bohrium, cadmium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form metal aquo complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be cobalt, and at least one of actinium,bohrium, cadmium, chromium, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form metal aquo complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe copernicium, and at least one of actinium, bohrium, cadmium,chromium, cobalt, copernicium, copper, darmstadtium, dubnium, gold,hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form metal aquo complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe copper, and at least one of actinium, bohrium, cadmium, chromium,cobalt, copernicium, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be darmstadtium,and at least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be dubnium, andat least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, gold, hafnium, hassium, iridium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, palladium, platinum, rhenium, rhodium, roentgenium, ruthenium,rutherfordium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be gold, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form metal aquo complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be hafnium, and at least one of actinium,bohrium, cadmium, chromium, cobalt, copernicium, copper, darmstadtium,dubnium, gold, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form metal aquo complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe hassium, and at least on of actinium, bohrium, cadmium, chromium,cobalt, copernicium, copper, darmstadtium, dubnium, gold, hafnium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be iridium, andat least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, palladium, platinum, rhenium, rhodium, roentgenium, ruthenium,rutherfordium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be iron, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form metal aquo complexes. In anotherembodiment, the mineral cation of the mineral cation hexa- aqua complexand ionic salt composition may be lanthanum, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, manganese,mercury, molybdenum, nickel, niobium, osmium, palladium, platinum,rhenium, rhodium, roentgenium, ruthenium, rutherfordium, scandium,seaborgium, silver, tantalum, technetium, titanium, tungsten, vanadium,yttrium, zinc, or zirconium and all other forms of these minerals thatare able to form metal aquo complexes. In another embodiment, themineral cation of the mineral cation hexa-aqua complex and ionic saltcomposition may be is manganese, and at least one of actinium, bohrium,cadmium, chromium, cobalt, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,roentgenium, ruthenium, rutherfordium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formmetal aquo complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may bemercury, and at least one of actinium, bohrium, cadmium, chromium,cobalt, copernicium, copper, darmstadtium, dubnium, gold, hafnium,hassium, iridium, iron, lanthanum, manganese, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be molybdenum,and at least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, nickel, niobium, osmium,palladium, platinum, rhenium, rhodium, roentgenium, ruthenium,rutherfordium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be nickel, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form metal aquo complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be niobium, and at least one of actinium,bohrium, cadmium, chromium, cobalt, copernicium, copper, darmstadtium,dubnium, gold, hafnium, hassium, iridium, iron, lanthanum, manganese,mercury, molybdenum, nickel, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form metal aquo complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe osmium, and at least one of actinium, bohrium, cadmium, chromium,cobalt, copernicium, copper, darmstadtium, dubnium, gold, hafnium,hassium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be palladium,and at least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, platinum, rhenium, rhodium, roentgenium, ruthenium,rutherfordium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be platinum, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,rhenium, rhodium, roentgenium, ruthenium, rutherfordium, scandium,seaborgium, silver, tantalum, technetium, titanium, tungsten, vanadium,yttrium, zinc, or zirconium and all other forms of these minerals thatare able to form metal aquo complexes. In another embodiment, themineral cation of the mineral cation hexa-aqua complex and ionic saltcomposition may be rhenium, and at least one of actinium, bohrium,cadmium, chromium, cobalt, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhodium,roentgenium, ruthenium, rutherfordium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formmetal aquo complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may berhodium, and at least one of actinium, bohrium, cadmium, chromium,cobalt, copernicium, copper, darmstadtium, dubnium, gold, hafnium,hassium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be roentgenium,and at least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, ruthenium,rutherfordium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be ruthenium, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, rutherfordium, scandium,seaborgium, silver, tantalum, technetium, titanium, tungsten, vanadium,yttrium, zinc, or zirconium and all other forms of these minerals thatare able to form metal aquo complexes. In another embodiment, themineral cation of the mineral cation hexa-aqua complex and ionic saltcomposition may be rutherfordium, and at least one of actinium, bohrium,cadmium, chromium, cobalt, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be scandium, andat least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be seaborgium, and at least oneof actinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, silver, tantalum, technetium, titanium, tungsten, vanadium,yttrium, zinc, or zirconium and all other forms of these minerals thatare able to form metal aquo complexes. In another embodiment, themineral cation of the mineral cation hexa-aqua complex and ionic saltcomposition may be silver, and at least one of actinium, bohrium,cadmium, chromium, cobalt, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formmetal aquo complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may betantalum, and at least one of actinium, bohrium, cadmium, chromium,cobalt, copernicium, copper, darmstadtium, dubnium, gold, hafnium,hassium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,roentgenium, ruthenium, rutherfordium, scandium, seaborgium, silver,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be technetium,and any one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form metal aquo complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be titanium and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, tungsten, vanadium,yttrium, zinc, or zirconium and all other forms of these minerals thatare able to form metal aquo complexes. In another embodiment, themineral cation of the mineral cation hexa-aqua complex and ionic saltcomposition may be tungsten, and at least on of actinium, bohrium,cadmium, chromium, cobalt, copernicium, copper, darmstadtium, dubnium,gold, hafnium, hassium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, roentgenium, ruthenium, rutherfordium, scandium, seaborgium,silver, tantalum, technetium, titanium, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formmetal aquo complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may bevanadium, and at least one of actinium, bohrium, cadmium, chromium,cobalt, copernicium, copper, darmstadtium, dubnium, gold, hafnium,hassium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,roentgenium, ruthenium, rutherfordium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be yttrium, andat least one of actinium, bohrium, cadmium, chromium, cobalt,copernicium, copper, darmstadtium, dubnium, gold, hafnium, hassium,iridium, iron, lanthanum, manganese, mercury, molybdenum, nickel,niobium, osmium, palladium, platinum, rhenium, rhodium, roentgenium,ruthenium, rutherfordium, scandium, seaborgium, silver, tantalum,technetium, titanium, tungsten, vanadium, zinc, or zirconium and allother forms of these minerals that are able to form metal aquocomplexes. In another embodiment, the mineral cation of the mineralcation -aqua complex and ionic salt composition may be zinc, and atleast one of actinium, bohrium, cadmium, chromium, cobalt, copernicium,copper, darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron,lanthanum, manganese, mercury, molybdenum, nickel, niobium, osmium,palladium, platinum, rhenium, rhodium, roentgenium, ruthenium,rutherfordium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, or zirconium and all other formsof these minerals that are able to form metal aquo complexes. In anotherembodiment, the cat mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be zirconium, and at least one ofactinium, bohrium, cadmium, chromium, cobalt, copernicium, copper,darmstadtium, dubnium, gold, hafnium, hassium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, roentgenium, ruthenium, rutherfordium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, or zinc and all other forms of these minerals thatare able to form metal aquo complexes.

In another embodiment, the mineral cation of the mineral cationhexa-aqua complex and ionic salt composition may be at least one of, orany combination of, actinium, cadmium, chromium, cobalt, copper, gold,hafnium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be actinium, and at least one of cadmium,chromium, cobalt, copper, gold, hafnium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may becadmium, and at least one of actinium, chromium, cobalt, copper, gold,hafnium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be chromium, and at least one ofactinium, cadmium, cobalt, copper, gold, hafnium, iridium, iron,lanthanum, manganese, mercury, molybdenum, nickel, niobium, osmium,palladium, platinum, rhenium, rhodium, ruthenium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe cobalt, and at least one of actinium, cadmium, chromium, copper,gold, hafnium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be copper, and at least one of actinium,cadmium, chromium, cobalt, gold, hafnium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may be gold,and at least one of actinium, cadmium, chromium, cobalt, copper,hafnium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be hafnium, and at least one of actinium,cadmium, chromium, cobalt, copper, gold, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may beiridium, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be iron, and at least one of actinium,cadmium, chromium, cobalt, copper, gold, hafnium, iridium, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may belanthanum, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be manganese, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, mercury, molybdenum, nickel, niobium, osmium,palladium, platinum, rhenium, rhodium, ruthenium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe mercury, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be molybdenum, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, manganese, mercury, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may benickel, and at least one of actinium, cadmium, chromium, cobalt, copper,gold, hafnium, iridium, iron, lanthanum, manganese, mercury, molybdenum,niobium, osmium, palladium, platinum, rhenium, rhodium, ruthenium,scandium, seaborgium, silver, tantalum, technetium, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be niobium, and at least one of actinium,cadmium, chromium, cobalt, copper, gold, hafnium, iridium, iron,lanthanum, manganese, mercury, molybdenum, nickel, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may beosmium , and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be palladium, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, platinum, rhenium, rhodium, ruthenium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe platinum, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be rhenium, and at least one of actinium,cadmium, chromium, cobalt, copper, gold, hafnium, iridium, iron,lanthanum, manganese, mercury, molybdenum, nickel, niobium, osmium,palladium, platinum, rhodium, ruthenium, scandium, seaborgium, silver,tantalum, technetium, titanium, tungsten, vanadium, yttrium, zinc, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may berhodium, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,ruthenium, scandium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be ruthenium, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, palladium, platinum, rhenium, rhodium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe scandium, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, ruthenium, seaborgium, silver, tantalum, technetium, titanium,tungsten, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be seaborgium, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, palladium, platinum, rhenium, rhodium, ruthenium, scandium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe silver, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, ruthenium, scandium, seaborgium, tantalum, technetium,titanium, tungsten, vanadium, yttrium, zinc, or zirconium and all otherforms of these minerals that are able to form hexa-aqua complexes. Inanother embodiment, the mineral cation of the mineral cation and ionicsalt composition may be tantalum, and at least one of actinium, cadmium,chromium, cobalt, copper, gold, hafnium, iridium, iron, lanthanum,manganese, mercury, molybdenum, nickel, niobium, osmium, palladium,platinum, rhenium, rhodium, ruthenium, scandium, seaborgium, silver,technetium, titanium, tungsten, vanadium, yttrium, zinc, or zirconiumand all other forms of these minerals that are able to form hexa-aquacomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be technetium,and at least one of actinium, cadmium, chromium, cobalt, copper, gold,hafnium, iridium, iron, lanthanum, manganese, mercury, molybdenum,nickel, niobium, osmium, palladium, platinum, rhenium, rhodium,ruthenium, scandium, seaborgium, silver, tantalum, titanium, tungsten,vanadium, yttrium, zinc, or zirconium and all other forms of theseminerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be titanium, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, palladium, platinum, rhenium, rhodium, ruthenium, scandium,seaborgium, silver, tantalum, technetium, tungsten, vanadium, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa-aqua complex and ionic salt composition maybe tungsten, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, ruthenium, scandium, seaborgium, silver, tantalum, technetium,titanium, vanadium, yttrium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be vanadium, and at least one ofactinium, cadmium, chromium, cobalt, copper, gold, hafnium, iridium,iron, lanthanum, manganese, mercury, molybdenum, nickel, niobium,osmium, palladium, platinum, rhenium, rhodium, ruthenium, scandium,seaborgium, silver, tantalum, technetium, titanium, tungsten, yttrium,zinc, or zirconium and all other forms of these minerals that are ableto form hexa-aqua complexes. In another embodiment, the mineral cationof the mineral cation hexa- aqua complex and ionic salt composition maybe yttrium, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, ruthenium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, zinc, or zirconium and all other forms ofthese minerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be zinc, and at least one of actinium,cadmium, chromium, cobalt, copper, gold, hafnium, iridium, iron,lanthanum, manganese, mercury, molybdenum, nickel, niobium, osmium,palladium, platinum, rhenium, rhodium, ruthenium, scandium, seaborgium,silver, tantalum, technetium, titanium, tungsten, vanadium, yttrium, orzirconium and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may bezirconium, and at least one of actinium, cadmium, chromium, cobalt,copper, gold, hafnium, iridium, iron, lanthanum, manganese, mercury,molybdenum, nickel, niobium, osmium, palladium, platinum, rhenium,rhodium, ruthenium, scandium, seaborgium, silver, tantalum, technetium,titanium, tungsten, vanadium, yttrium, or zinc and all other forms ofthese minerals that are able to form hexa-aqua complexes.

In another embodiment, the mineral cation of the mineral cationhexa-aqua complex and ionic salt composition may be at least one of, orany combination of, chromium, cobalt, copper, gold, iron, manganese,magnesium, molybdenum, nickel, platinum, silver, vanadium, or zinc andall other forms of these minerals that are able to form hexa-aquacomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be chromium, andat least one of cobalt, copper, gold, iron, manganese, magnesium,molybdenum, nickel, platinum, silver, vanadium, or zinc and all otherforms of these minerals that are able to form hexa-aqua complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be cobalt, and at least one ofchromium, copper, gold, iron, manganese, magnesium, molybdenum, nickel,platinum, silver, vanadium, or zinc and all other forms of theseminerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be copper, and at least one of chromium,cobalt, gold, iron, manganese, magnesium, molybdenum, nickel, platinum,silver, vanadium, or zinc and all other forms of these minerals that areable to form hexa-aqua complexes. In another embodiment, the mineralcation of the mineral cation hexa-aqua complex and ionic saltcomposition may be gold, and at least one of chromium, cobalt, copper,iron, manganese, magnesium, molybdenum, nickel, platinum, silver,vanadium, or zinc and all other forms of these minerals that are able toform hexa-aqua complexes. In another embodiment, the mineral cation ofthe mineral cation hexa-aqua complex and ionic salt composition may beiron, and at least one of chromium, cobalt, copper, gold, manganese,magnesium, molybdenum, nickel, platinum, silver, vanadium, or zinc andall other forms of these minerals that are able to form hexa-aquacomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be manganese,and any one of chromium, cobalt, copper, gold, iron, magnesium,molybdenum, nickel, platinum, silver, vanadium, or zinc and all otherforms of these minerals that are able to form hexa-aqua complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be magnesium, and at least one ofchromium, cobalt, copper, gold, iron, manganese, molybdenum, nickel,platinum, silver, vanadium, or zinc and all other forms of theseminerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be molybdenum, and at least one ofchromium, cobalt, copper, gold, iron, manganese, magnesium, nickel,platinum, silver, vanadium, or zinc and all other forms of theseminerals that are able to form hexa-aqua complexes. In anotherembodiment, the mineral cation of the mineral cation hexa-aqua complexand ionic salt composition may be nickel, and at least one of chromium,cobalt, copper, gold, iron, manganese, magnesium, molybdenum, platinum,silver, vanadium, or zinc and all other forms of these minerals that areable to form hexa-aqua complexes. In another embodiment, the mineralcation of the mineral cation hexa-aqua complex and ionic saltcomposition may be platinum, and at least one of chromium, cobalt,copper, gold, iron, manganese, magnesium, molybdenum, silver, vanadium,or zinc and all other forms of these minerals that are able to formhexa-aqua complexes. In another embodiment, the mineral cation of themineral cation hexa-aqua complex and ionic salt composition may besilver, and at least one of chromium, cobalt, copper, gold, iron,manganese, magnesium, molybdenum, nickel, platinum, vanadium, or zincand all other forms of these minerals that are able to form hexa-aquacomplexes. In another embodiment, the mineral cation of the mineralcation hexa-aqua complex and ionic salt composition may be vanadium, andat least one of chromium, cobalt, copper, gold, iron, manganese,magnesium, molybdenum, nickel, platinum, silver, or zinc and all otherforms of these minerals that are able to form hexa-aqua complexes. Inanother embodiment, the mineral cation of the mineral cation hexa-aquacomplex and ionic salt composition may be zinc, and at least one ofchromium, cobalt, copper, gold, iron, manganese, magnesium, molybdenum,nickel, platinum, silver, or vanadium and all other forms of theseminerals that are able to form hexa-aqua complexes.

In certain embodiments, the mineral cation of the mineral cationhexa-aqua complex and ionic salt composition may be copper, zinc, andmagnesium.

The composition containing the mineral cation hexa-aqua complex isaccompanied by an ionic salt in a pharmaceutically acceptable carrier.The composition allows the ionic salt to transport through a biologicalsystem to a target cell.

In certain embodiments, the ionic salt the of the mineral cationhexa-aqua complex and ionic salt composition may be at least one of, orany combination of, bicarbonate, calcium, chloride, sodium, sulfur,nitrogen, phosphorous, or potassium. In another embodiment, the ionicsalt the of the mineral cation hexa-aqua complex and ionic saltcomposition may be bicarbonate, and at least one of calcium, chloride,sodium, sulfur, nitrogen, phosphorous, and potassium. In anotherembodiment, the ionic salt the of the mineral cation hexa-aqua complexand ionic salt composition may be calcium, and at least one ofbicarbonate, chloride, sodium, sulfur, nitrogen, phosphorous, orpotassium. In another embodiment, the ionic salt the of the mineralcation hexa-aqua complex and ionic salt composition may be chloride, andat least one of bicarbonate, calcium, sodium, sulfur, nitrogen,phosphorous, or potassium. In another embodiment, the ionic salt the ofthe mineral cation hexa-aqua complex and ionic salt composition may besodium, and at least one of bicarbonate, calcium, chloride, sodium,sulfur, nitrogen, phosphorous, or potassium. In another embodiment theionic salt of the mineral cation hexa-aqua complex and ionic saltcomposition may be sodium, and at least one of bicarbonate, calcium,chloride, sulfur, nitrogen, phosphorous, or potassium. In anotherembodiment, the ionic salt the of the mineral cation hexa-aqua complexand ionic salt composition may be sulfur, and at least one ofbicarbonate, calcium, chloride, sodium, nitrogen, phosphorous, orpotassium. In another embodiment, the ionic salt the of the mineralcation hexa-aqua complex and ionic salt composition may be nitrogen, andat least one of bicarbonate, calcium, chloride, sodium, sulfur,phosphorous, or potassium. In another embodiment, the ionic salt of themineral cation hexa-aqua complex and ionic salt composition may bephosphorus, and at least one of bicarbonate, calcium, chloride, sodium,sulfur, nitrogen, or potassium. In another embodiment, the ionic saltthe of the mineral cation hexa-aqua complex and ionic salt compositionmay be potassium, and at least one of bicarbonate, calcium, chloride,sodium, sulfur, nitrogen, or phosphorous.

In certain embodiments, the ionic salt of the mineral cation hexa-aquacomplex and ionic salt composition may be ammonium, and hydrogensulfate.

In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may contain trace amounts of hydrogen cations. Inanother embodiment, the mineral cation hexa-aqua complex and ionic saltcomposition may contain about 0.01% to about 0.25% w/w.

In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may comprise about 1% to about 5% cationic mineralhexaaqua complexes, about 1% to about 15% ionic salts, and about 80%-98%carrier. In another embodiment, the mineral cation hexa-aqua complex andionic salt composition may comprise about 5% to about 10% cationicmineral hexaaqua complexes, about 15% to about 25% ionic salts, andabout 65% to about 80% carrier.

In another embodiment, the mineral cation hexa-aqua complex and ionicsalt composition may comprise about 10% to about 20% cationic mineralhexaaqua complexes, about 25% to about 50% ionic salts, and about 30% toabout 65% carrier. In another embodiment, the mineral cation hexa-aquacomplex and ionic salt composition may comprise about 20% to about 30%cationic mineral hexaaqua complexes, about 50% to about 70% ionic salts,and about 0%-30% carrier.

In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may comprise hexaaquacopper (II) ion, hexaaquazinc (II)ion, hexaaquamagnesium (II) ion, hydrogen cation, ammonium, hydrogensulfate, and water. In certain embodiments, the mineral cation hexa-aquacomplex and ionic salt composition may comprise hexaaquacopper (II) ion,hexaaquazinc (II) ion, hexaaquamagnesium (II) ion, hydrogen cation,ammonium, hydrogen sulfate, and water, wherein the hexaaquacopper (II)ion may be about 1.0% to about 2.5% w/w, the hexaaquazinc (II) ion isabout 3.5% to about 5.0% w/w, the hexaaquamagnesium (II) ion may beabout 1.0% to about 2.5% w/w, the hydrogen cation may be about 0.04% toabout 0.14%, the ammonium may be about 1.0% to about 2.5% w/w, thehydrogen sulfate may be about 18% to about 20% w/w and the water may beabout 70.0% to about 71.5% w/w.

In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may be diluted to avoid any complications associatedwith the pH of the composition.

The use of botanicals, vitamin and mineral supplements, and formulationadditives may improve the performance of the mineral cation hexa-aquacomplex and ionic salt composition. In some embodiments, the mineralcation hexa-aqua complex and ionic salt composition may further comprisebotanical extracts and isolations. In one embodiment, the botanicalextract of the mineral cation hexa-aqua complex and ionic saltcomposition may be at least one of, or any combination of, Graviola(Annona muricate), Bitter Melon (Momordica charantia), Esplanheira Santa(Maytenus illcifolia), Mullaca (Physolis angulate), Vasourinho (Scopariadulcis), Mutamba (Guazuma ulmifola), Suma (Pfaffia paniculata), Cat'sClaw (Uncaria tomantosa), or Blood Root (Sanguinaria canadensis). Inanother embodiment, the botanical extract of the mineral cationhexa-aqua complex and ionic salt composition may be Graviola (Annonamuricate), and at least one of Bitter Melon (Momordica charantia),Esplanheira Santa (Maytenus illcifolia), Mullaca (Physolis angulate),Vasourinho (Scoparia dulcis), Mutamba (Guazuma ulmifola), Suma (Pfaffiapaniculata), Cat's Claw (Uncaria tomantosa), or Blood Root (Sanguinariacanadensis). In another embodiment, the botanical extract of the mineralcation hexa-aqua complex and ionic salt composition may be Bitter Melon(Momordica charantia), and at least one of Graviola (Annona muricate),Esplanheira Santa (Maytenus illcifolia), Mullaca (Physolis angulate),Vasourinho (Scoparia dulcis), Mutamba (Guazuma ulmifola), Suma (Pfaffiapaniculata), Cat's Claw (Uncaria tomantosa), or Blood Root (Sanguinariacanadensis). In another embodiment, the botanical extract of the mineralcation hexa-aqua complex and ionic salt composition may be EsplanheiraSanta (Maytenus illcifolia), and at least one of Graviola (Annonamuricate), Bitter Melon (Momordica charantia), Mullaca (Physolisangulate), Vasourinho (Scoparia dulcis), Mutamba (Guazuma ulmifola),Suma (Pfaffia paniculata), Cat's Claw (Uncaria tomantosa), or Blood Root(Sanguinaria canadensis). In another embodiment, the botanical extractof the mineral cation hexa-aqua complex and ionic salt composition maybe Mullaca (Physolis angulate), and at least one of Graviola (Annonamuricate), Bitter Melon (Momordica charantia), Esplanheira Santa(Maytenus illcifolia), Vasourinho (Scoparia dulcis), Mutamba (Guazumaulmifola), Suma (Pfaffia paniculata), Cat's Claw (Uncaria tomantosa), orBlood Root (Sanguinaria canadensis). In another embodiment, thebotanical extract of the mineral cation hexa-aqua complex and ionic saltcomposition may be Vasourinho (Uncaria tomantosa), and at least one ofGraviola (Annona muricate), Bitter Melon (Momordica charantia),Esplanheira Santa (Maytenus illcifolia), Mullaca (Physolis angulate),Mutamba (Guazuma ulmifola), Suma (Pfaffia paniculata), Cat's Claw(Uncaria tomantosa), or Blood Root (Sanguinaria canadensis). In anotherembodiment, the botanical extract of the mineral cation hexa-aquacomplex and ionic salt composition may be Mutamba (Guazuma ulmifola),and at least one of Graviola (Annona muricate), Bitter Melon (Momordicacharantia), Esplanheira Santa (Maytenus illcifolia), Mullaca (Physolisangulate), Vasourinho (Scoparia dulcis), Suma (Pfaffia paniculata),Cat's Claw (Uncaria tomantosa), or Blood Root (Sanguinaria canadensis).In another embodiment, the botanical extract of the mineral cationhexa-aqua complex and ionic salt composition may be Suma (Pfaffiapaniculata), and at least one of Graviola (Annona muricate), BitterMelon (Momordica charantia), Esplanheira Santa (Maytenus illcifolia),Mullaca (Physolis angulate), Vasourinho (Scoparia dulcis), Mutamba(Guazuma ulmifola), Cat's Claw (Uncaria tomantosa), or Blood Root(Sanguinaria canadensis). In another embodiment, the botanical extractof the mineral cation hexa-aqua complex and ionic salt composition maybe Cat's Claw (Uncaria tomantosa), and at least one of Graviola (Annonamuricate), Bitter Melon (Momordica charantia), Esplanheira Santa(Maytenus illcifolia), Mullaca (Physolis angulate), Vasourinho (Scopariadulcis), Mutamba (Guazuma ulmifola), Suma (Pfaffia paniculata), or BloodRoot (Sanguinaria canadensis). In another embodiment, the botanicalextract of the mineral cation hexa-aqua complex and ionic saltcomposition may be Blood Root (Sanguinaria canadensis), and at least oneof Graviola (Annona muricate), Bitter Melon (Momordica charantia),Esplanheira Santa (Maytenus illcifolia), Mullaca (Physolis angulate),Vasourinho (Scoparia dulcis), Mutamba (Guazuma ulmifola), Suma (Pfaffiapaniculata), or Cat's Claw (Uncaria tomantosa).

Composition Characteristics

The mineral cation hexa-aqua complex and ionic salt composition is aunique ligand binding delivery system that moves ionic material throughvarious tissue layers and across the semi-permeable membranes of cellsthroughout a subject. The ionic content delivered intracellularlyexhibits numerous beneficial characteristics. The mineral cationhexa-aqua complex and ionic salt composition, at appropriateconcentration and proportion, is non-toxic to healthy cells of asubject, wherein the subject is a higher organism. In certainembodiments, the redox potential of the mineral cation hexa-aqua complexand ionic salt composition may be at least 450 Mv, wherein free radicalsassociated with metabolic function and disease response may be managed.In certain embodiments, the antioxidant Oxygen Radical AbsorbanceCapacity (ORAC) of the mineral cation hexa-aqua complex and ionic saltcomposition may measure about 1026 μMTE, wherein free radicalsassociated with metabolic function and disease response may be managed.In certain embodiments, the mineral cation hexa-aqua complex and ionicsalt composition may provide greater bioavailability and time of actionthan ingested foods and mineral supplements. In certain embodiments, thepH of the mineral cation hexa-aqua complex and ionic salt compositionregisters as acidic (pH<1.0). The metal ions with positive chargesreside in the middle of the ligand and pulls on the oxygen molecule ofwater inwards exposing the hydrogen ion to the outside of the ligand ofthe metal-aquo complex making the ligand as a whole act similarly tothat of a hydrogen atom thereby making the ligand structure appear acid,however the product does not display a high acid profile and is easy tohandle in the lab and may be safe for human consumption.

Lyme Disease

Treatment for Lyme Disease traditionally includes the use ofantibiotics. The use of such treatments can however conclude withpatients continuing to experience disease-associated symptoms, which hasresulted in concern regarding the effectiveness of such treatmentmethods. Antibiotics have largely shown to be effective in treating LymeDisease, especially when administered during early stages of infection,however bacteria are known to develop and deploy survival mechanisms,such as antibiotic resistance or tolerance. Borrelia burgdorferi, thepathogenic bacteria that causes Lyme Disease, has been shown toresponsively adapt to host ecosystems through persistence survival viadynamic changes in morphology and formation of biofilm-like aggregates,which possess degrees of antibiotic tolerance. Thus, a strategy notinvolving the use of antibiotics was evaluated for the treatment of LymeDisease. More specifically, the use of a mineral cation hexa-aquacomplex and ionic salt composition was assessed for its effectiveness inalleviating symptoms and treating Lyme Disease.

All treatments comprise the mineral cation hexa-aqua complex and ionicsalt composition. Exemplary subjects may be seropositive for IgGantibodies for Borrelia burgdorferi, optionally receive antibiotictreatments, and optionally, present evidence of spirochete in salivasamples. Subjects may present at least one Lyme Disease-associatedsymptom. Compositions for treatment of Lyme Disease may comprise(hexaaquacopper (II)ion (Cu(H2O)₆ ²⁺), hexaaquazzinc (II)ion (Zn(H2O)₆²⁺), hexaaquamagnesium (II)ion (Mg(H2O)₆ ²⁺), hydrogen cation (H⁺),ammonium (NH⁴⁺), hydrogen sulfate (HSO⁴⁻), and water(H₂O)), wherein thehexaaquacopper (II)ion ranged from about 1.0 to about 2.5% w/w, thehexaaquazinc (II)ion ranged from about 3.5% to about 5.0% w/w, thehexaaquamagnesium (II)ion ranged from about 1.0% to about 2.5% w/w, thehydrogen cation ranged from about 0.04% to about 0.14%, the ammoniumranged from about 1.0% to about 2.5% w/w, the hydrogen sulfate rangedfrom about 18% to about 20% w/w and the water ranged from about 70.0% toabout 71.5% w/w. via nebulization. The course of treatment may comprise1.0 mL of the mineral cation hexa-aqua complex and ionic saltcomposition daily for 60 days.

Statements Regarding Variations

Where the terms “comprise”, “comprises”, “comprised”, or “comprising”are used herein, they are to be interpreted as specifying the presenceof the stated features, integers, steps, or components referred to, butnot to preclude the presence or addition of one or more other feature,integer, step, component, or group thereof. Separate embodiments of thedisclosure are also intended to be encompassed wherein the terms“comprising” or “comprise(s)” or “comprised” are optionally replacedwith the terms, analogous in grammar, e.g.; “consisting/consist(s)” or“consisting essentially of/consist(s)essentially of to thereby describefurther embodiments that are not necessarily coextensive. Forclarification, as used herein “comprising is synonymous with “having,”“including,” “containing,” or “characterized by,” and is inclusive oropen-ended and does not exclude additional, unrecited elements or methodsteps. As used herein, “consisting of” excludes any element, step,component, or ingredient not specified in the claim element. As usedherein, the term “about” refers to a quantity, level, value, number,frequency, percentage, dimension, size, amount, weight or length thatvaries by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% toa reference quantity, level, value, number, frequency, percentage,dimension, size, amount, weight or length. In any embodiment discussedin the context of a numerical value used in conjunction with the term“about,” it is specifically contemplated that the term about can beomitted. The disclosure illustratively described herein suitably may bepracticed in the absence of any element or elements, limitation orlimitations which is not specifically disclosed herein. The disclosurehas been described with reference to various specific and preferredembodiments and techniques. However, it should be understood that manyvariations and modifications may be made while remaining within thescope of the disclosure. It will be appreciated by one of ordinary skillin the art that compositions, methods, devices, device elements,materials, optional features, procedures and techniques other than thosespecifically described herein can be applied to the practice of thedisclosure as broadly disclosed herein without resort to undueexperimentation. All art-known functional equivalents of compositions,methods, devices, device elements, materials, procedures and techniquesdescribed herein; and portions thereof; are intended to be encompassedby this disclosure. Whenever a range is disclosed, all subranges andindividual values are intended to be encompassed. This disclosure is notto be limited by the embodiments disclosed, including any shown in thedrawings or exemplified in the specification, which are given by way ofexample or illustration and not of limitation. The compositions andmethods and accessory methods described herein as presentlyrepresentative of preferred embodiments are exemplary and are notintended as limitations on the scope of the disclosure.

EXAMPLES

The invention is now described with reference to the following Examples.These Examples are provided for the purpose of illustration only and theinvention should in no way be construed as being limited to theseExamples, but rather should be construed to encompass any and allvariations which become evident as a result of the teaching providedherein.

Without further description, it is believed that one of ordinary skillin the art can, using the preceding description and the followingillustrative examples, make and utilize the compounds of the presentinvention and practice the claimed methods. The following workingexamples, therefore, specifically point out the preferred embodiments ofthe present invention, and are not to be construed as limiting in anyway the remainder of the disclosure.

The materials and methods employed in these experiments are nowdescribed.

Example 1 Nebulization of the Mineral Cation Hexa-Aqua Complex and IonicSalt Composition for the Treatment of Lyme Disease Background

Treatment for Lyme Disease traditionally includes the use ofantibiotics. The use of such treatments can however conclude withpatients continuing to experience disease-associated symptoms, which hasresulted in concern regarding the effectiveness of such treatmentmethods. Antibiotics have largely shown to be effective in treating LymeDisease, especially when administered during early stages of infection,however bacteria are known to develop and deploy survival mechanisms,such as antibiotic resistance or tolerance. Borrelia burgdorferi, thepathogenic bacteria that causes Lyme Disease, has been shown toresponsively adapt to host ecosystems through persistence survival viadynamic changes in morphology and formation of biofilm-like aggregates,which possess degrees of antibiotic tolerance. Thus, a strategy notinvolving the use of antibiotics was evaluated for the treatment of LymeDisease. More specifically, the use of a mineral cation hexa-aquacomplex and ionic salt composition was assessed for its effectiveness inalleviating symptoms and treating Lyme Disease. Methods

Assessments were recorded via testimony. All treatments using themineral cation hexa-aqua complex and ionic salt composition werevoluntarily self-administered. Subjects included individuals who wereseropositive for IgG antibodies for Borrelia burgdorferi and who did notreceive antibiotic treatments, as well as individuals who wereseropositive for IgG antibodies for Borrelia burgdorferi and did receiveantibiotic treatments yet still had evidence of spirochete in salivasamples. Each subject indicated at least one Lyme Disease-associatedsymptom. Subjects at the time of treatment self-administered acomposition comprising (hexaaquacopper (II)ion (Cu(H2O)₆ ²⁺),hexaaquazzinc (II)ion (Zn(H2O)₆ ²⁺), hexaaquamagnesium (II)ion (Mg(H2O)₆²⁺), hydrogen cation (H⁺), ammonium (NH⁴⁺), hydrogen sulfate (HSO⁴⁻),and water(H₂O)), wherein the hexaaquacopper (II)ion ranged from about1.0 to about 2.5% w/w, the hexaaquazinc (II)ion ranged from about 3.5%to about 5.0% w/w, the hexaaquamagnesium (II)ion ranged from about 1.0%to about 2.5% w/w, the hydrogen cation ranged from about 0.04% to about0.14%, the ammonium ranged from about 1.0% to about 2.5% w/w, thehydrogen sulfate ranged from about 18% to about 20% w/w and the waterranged from about 70.0% to about 71.5% w/w. via nebulization. The courseof treatment comprised 1.0 mL of the mineral cation hexa-aqua complexand ionic salt composition daily for 60 days. Patients were thenre-evaluated for Lyme disease-associated symptoms post-treatment.

Results

All of the subjects who self-administered the cationic mineral reportedalleviation of at least one Lyme Disease-associated symptom. No negativereactions, side-effects, or worsening of Lyme Disease-related symptomswere reported.

General symptom as well as persistent symptoms resulting from LymeDisease can result in noticeable loss of health-related quality of life.Prolonged treatments using antibiotics has not been well elucidated andmay cause negative secondary effects. The proposed treatment method ofadministering the mineral cation hexa-aqua complex and ionic saltcomposition appeared initially successful in providing symptomalleviation.

INCORPORATION BY REFERENCE

All references, articles, publications, patents, patent publications,and patent applications cited herein are incorporated by reference intheir entireties for all purposes.

However, mention of any reference, article, publication, patent, patentpublication, and patent application cited herein is not, and should notbe taken as an acknowledgment or any form of suggestion that theyconstitute valid prior art or form part of the common general knowledgein any country in the world.

1-86. (canceled)
 87. A method for treating Lyme Disease in a subject inneed thereof, comprising administering to the subject a therapeuticallyeffective amount of a composition comprising hexaaquacopper ions,hexaaquazinc ions, hexaaquamagnesium ions, hydrogen cations, ammonium,hydrogen sulfate, and water.
 88. The method of claim 87, wherein thecomposition comprises hexaaquacopper ions in an amount of from about1.0% to about 2.5% w/w
 89. The method of claim 87, wherein thecomposition comprises hexaaquazinc ions in an amount of from about 3.5%to about 5.0% w/w.
 90. The method of claim 87, wherein the compositioncomprises hexaaquamagnesium ions in an amount of from about 1.0% toabout 2.5% w/w.
 91. The method of claim 87, wherein the compositioncomprises ammonium in an amount of from about 1.0% to about 2.5% w/w.92. The method of claim 87, wherein the composition comprises hydrogensulfate in an amount of from about 18% to about 20% w/w.
 93. The methodof claim 87, wherein the composition comprises water in an amount offrom about 70% to about 71.5% w/w.
 94. The method of claim 87, whereinsaid treating further comprises treating a disorder secondary orco-morbid with Lyme Disease.
 95. The method of claim 87, wherein thecomposition is administered systemically.
 96. The method of claim 87,wherein the composition is administered orally, intranasally,intravenously, intraperitoneally, subcutaneously or intramuscularly. 97.The method of claim 87, wherein the composition is administered locally.98. The method of claim 87, wherein the composition is administeredtopically, intraocularly, intraspinally, intracerebroventricularly,intraosseously or intratumorally.
 99. The method of claim 87, whereinthe composition further comprises a pharmaceutically acceptable carrier.100. The method of claim 87, wherein the composition further comprisesone or more botanical agent(s).
 101. The method of claim 100, whereinthe one or more botanical agent(s) comprises Graviola (Annona muricate),Bitter Melon (Momordica charantia), Esplanheira Santa (Maytenusillcifolia), Mullaca (Physolis angulate), Vasourinho (Scoparia dulcis),Mutamba (Guazuma ulmifola), Suma (Pfaffia paniculata), Cat's Claw(Uncaria tomantosa)and Blood Root (Sanguinaria canadensis).
 102. Aformulation comprising the composition of claim 87, wherein theformulation is suitable for administration in a liquid form, asuspension form, a rehydrated form, a droplet form, an aerosol form, avaporized form, a nebulized form, a semi-solid form, a solid form, apill form, a tablet form or a capsule form.
 103. The method of claim 87,wherein the hexaaquacopper ions are hexaaquacopper (II) ions, thehexaaquazinc ions are hexaaquazinc (II) ions, and the hexaauqamagnesiumions are hexaaquamagnesium (II) ions.
 104. The method of claim 87,wherein the composition is administered by a nebulizer.
 105. The methodof claim 87, wherein said treating further comprises alleviatingErythema migrans (EM)rashes, swollen lymph nodes, arthritis and swellingof joints, carditis and heart arrhythmia, neuritis, neurocognitiveimpairment, facial palsy, intermittent pain or paresthesia of the body,fever, fatigue, dizziness, and/or shortness of breath.
 106. The methodof claim 87, wherein said treating further comprises treatingPost-Treatment Lyme Disease Syndrome (PTLDS), chronic Lyme arthritis,and/or chronic Lyme neuroborreliosis.